Skip to main content
Research

Publications: Prof David Baker

Baker D, Vainchtein ID ( 2022 ) . Characterizing microglial gene expression in a model of secondary progressive MS . Glia
Kipnis Y, Chaib AO, Vorobieva AA, Cai G, Reggiano G, Basanta B, Kumar E, Mittl PRE et al. ( 2022 ) . Design and optimization of enzymatic activity in a de novo β-barrel scaffold . Protein Science vol. 31 , ( 11 )
Park JS, Choi J, Cao L, Mohanty J, Suzuki Y, Park A, Baker D, Schlessinger J et al. ( 2022 ) . Isoform-specific inhibition of FGFR signaling achieved by a de-novo-designed mini-protein . Cell Reports vol. 41 , ( 4 )
James SA, Parker A, Purse C, Telatin A, Baker D, Holmes S, Durham J, Funnell SGP et al. ( 2022 ) . The Cynomolgus Macaque Intestinal Mycobiome Is Dominated by the Kazachstania Genus and K. pintolopesii Species . Journal of Fungi vol. 8 , ( 10 )
Allen-Philbey K, Stennett A, Begum T, Johnson AC, MacDougall A, Green S, Dobson R, Giovannoni G et al. ( 2022 ) . Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 65 ,
Schmierer K, Redha I, Hammond V, Baker D, Barkhof F, Hooper R, Rashid W, Singh-Curry V et al. ( 2022 ) . 152 AttackMS natalizumab for the treatment of people with inflammatory demyeli- nation suggestive of multiple sclerosis . Journal of Neurology Neurosurgery & Psychiatry . vol. 93 ,
Schmierer K, Baker D, Nawaz T, Allen-Philbey K, Barkhof F, Chataway J, Hooper R, Mihaylova B et al. ( 2022 ) . 153 ChariotMS – cladribine to halt deterioration in people with advanced multiple sclerosis (pwAMS) . Journal of Neurology Neurosurgery & Psychiatry . vol. 93 ,
Tallantyre EC, Scurr MJ, Vickaryous N, Richards A, Anderson V, Baker D, Chance R, Evangelou N et al. ( 2022 ) . Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 64 ,
Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R ( 2022 ) . Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals? . Clin Exp Immunol vol. 207 , ( 3 ) 263 - 271 .
Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R ( 2022 ) . Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals? . Clinical and Experimental Immunology vol. 207 , ( 3 ) 263 - 271 .
Guo L, Luong V, Gregson A, Baker D, Selwood D, Cordeiro MF ( 2022 ) . VSN16S, an agonist of the cannabinoid receptor, reduces IOP profiles and exhibits neuroprotective properties in a rat model of glaucoma . Acta Ophthalmologica vol. 100 , ( S267 )
Quijano-Rubio A, Bhuiyan AM, Yang H, Leung I, Bello E, Ali LR, Zhangxu K, Perkins J et al. ( 2022 ) . A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy . Nature Biotechnology
Licht-Mayer S, Campbell GR, Mehta AR, McGill K, Symonds A, Al-Azki S, Pryce G, Zandee S et al. ( 2022 ) . Axonal response of mitochondria to demyelination and complex IV activity within demyelinated axons in experimental models of multiple sclerosis . Neuropathology and Applied Neurobiology
Said MY, Kang CS, Wang S, Sheffler W, Salveson PJ, Bera AK, Kang A, Nguyen H et al. ( 2022 ) . Exploration of Structured Symmetric Cyclic Peptides as Ligands for Metal-Organic Frameworks . Chemistry of Materials
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al. ( 2022 ) . Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study . Multiple Sclerosis and Related Disorders vol. 57 ,
Hurley MJ, Deacon RMJ, Chan AWE, Baker D, Selwood DL, Cogram P ( 2022 ) . Reversal of behavioural phenotype by the cannabinoid-like compound VSN16R in fragile X syndrome mice . Brain vol. 145 , ( 1 ) 76 - 82 .
Baker D ( 2021 ) . CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis . Multiple Sclerosis and Related Disorders
Klima JC, Doyle LA, Lee JD, Rappleye M, Gagnon LA, Lee MY, Barros EP, Vorobieva AA et al. ( 2021 ) . Incorporation of sensing modalities into de novo designed fluorescence-activating proteins . Nature Communications vol. 12 , ( 1 )
Marta M, Baker D, Creeke P, Pryce G, Gnanapavan S, Giovannoni G ( 2021 ) . Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report . Multiple Sclerosis and Related Disorders vol. 56 ,
Allen-Philbey K, De Trane S, Mao Z, Álvarez-González C, Mathews J, MacDougall A, Stennett A, Zhou X et al. ( 2021 ) . Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients . Therapeutic Advances in Neurological Disorders vol. 14 ,
Dobson R, Baker D, Kang A, Schmierer K, Giovannoni G ( 2021 ) . COVID-19 vaccine response in people with multiple sclerosis . Annals of Neurology
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al. ( 2021 ) . Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 514 - 515 .
Vickaryous N, Asardag AN, Chance R, Jones M, Bestwick J, Shah SN, George K, Schmierer K et al. ( 2021 ) . Seroconversion following vaccination against SARS-CoV-2 in people with MS: impact of disease modifying therapy . MULTIPLE SCLEROSIS JOURNAL vol. 27 , ( 2_SUPPL ) 775 - 776 .
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Up to 6 years follow-up of people with MS (n=250) receiving cladribine . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 546 - 547 .
Rupnik M, Baker D, Selwood DL ( 2021 ) . Oligodendrocytes, BK channels and remyelination . F1000Research vol. 10 ,
Baker D, Asardag AN, Quinn OA, Efimov A, Kang AS ( 2021 ) . Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis . Hum Antibodies
Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA, Baker D ( 2021 ) . COVID-19 vaccines and multiple sclerosis disease-modifying therapies . Multiple Sclerosis and Related Disorders vol. 53 ,
Baker D, Hadjicharalambous C, Gnanapavan S, Giovannoni G ( 2021 ) . Can rheumatologists stop causing demyelinating disease? . Multiple Sclerosis and Related Disorders vol. 53 ,
Patel V, Efimov A, Baker D, Kang AS ( 2021 ) . Immunogenicity of biologics used in the treatment of moderate to severe psoriasis . Human Antibodies vol. 29 , ( 3 ) 171 - 178 .
Bqain M, Efimov A, Baker D, Kang AS ( 2021 ) . Immunogenicity of biologics used in the treatment of inflammatory bowel disease: A review . Human Antibodies
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 90 - 91 .
Zhang S, Chen J, Liu J, Pyles H, Baker D, Chen CL, De Yoreo JJ ( 2021 ) . Engineering Biomolecular Self-Assembly at Solid–Liquid Interfaces . Advanced Materials vol. 33 , ( 23 )
Schmierer K, Sørensen PS, Baker D ( 2021 ) . Highly effective disease-modifying treatment as initial MS therapy . Current Opinion in Neurology vol. 34 , ( 3 ) 286 - 294 .
Guo L, Luong V, Gregson A, Baker D, Selwood D, Cordeiro MF ( 2021 ) . VSN16S, an agonist of the cannabinoid receptor, reduces IOP profiles and exhibits neuroprotective properties in a rat model of glaucoma . INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE . vol. 62 ,
Dobson R, ALLEN-PHILBEY K, Giovannoni G, Baker D, Schmierer K ( 2021 ) . Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis . Multiple Sclerosis and Related Disorders
Smets I, Reyes S, Baker D, Giovannoni G ( 2021 ) . Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment . Multiple Sclerosis and Related Disorders vol. 50 ,
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Cladribine personalised dosing for active multiple sclerosis: BartsMS cohort follow-up . NEUROLOGY . vol. 96 ,
Thomson A, Dobson R, Baker D, Giovannoni G ( 2021 ) . Digesting science: Developing educational activities about multiple sclerosis, prevention and treatment to increase the confidence of affected families . Multiple Sclerosis and Related Disorders vol. 47 ,
Selwood DL, Rupnik M, Baker D ( 2021 ) . Oligodendrocytes, BK channels and the preservation of myelin . F1000Research vol. 10 ,
Sarwar MB, Yasir M, Alikhan NF, Afzal N, de Oliveira Martins L, Le Viet T, Trotter AJ, Prosolek SJ et al. ( 2021 ) . Sars-cov-2 variants of concern dominate in lahore, pakistan in april 2021 . Microbial Genomics vol. 7 , ( 11 )
Munger K, Kang A, Baker D, Goodman A, Samkoff L ( 2020 ) . Alemtuzumab depletion failure and neutralizing anti-drug antibodies: a case report and call for monitoring . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 258 - 258 .
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2020 ) . Cladribine personalised dosing to treat multiple sclerosis: observations in 208 patients . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 522 - 523 .
Lieberman D, Mangat H, Allen-Philbey K, Baker D, Barkhof F, Chandran S, Chapman C, Chataway J et al. ( 2020 ) . Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS) . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 212 - 213 .
Isaacs-Ten A, Echeandia M, Moreno-Gonzalez M, Brion A, Goldson A, Philo M, Patterson AM, Parker A et al. ( 2020 ) . Intestinal Microbiome-Macrophage Crosstalk Contributes to Cholestatic Liver Disease by Promoting Intestinal Permeability in Mice . Hepatology vol. 72 , ( 6 ) 2090 - 2108 .
Mateo-Casas M, Reyes S, De Trane S, Edwards F, Espasandin M, Anjorin G, Baker D, Schmierer K et al. ( 2020 ) . Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not? . eNeurologicalSci vol. 21 ,
Martin JT, Cottrell CA, Antanasijevic A, Carnathan DG, Cossette BJ, Enemuo CA, Gebru EH, Choe Y et al. ( 2020 ) . Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations . npj Vaccines vol. 5 , ( 1 )
Cunniffe N, Vuong KA, Ainslie D, Baker D, Beveridge J, Bickley S, Camilleri P, Craner M et al. ( 2020 ) . Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis . Journal of Neurology, Neurosurgery and Psychiatry
Amor S, Fernández Blanco L, Baker D ( 2020 ) . Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage . Clinical and Experimental Immunology vol. 202 , ( 2 ) 193 - 209 .
Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L et al. ( 2020 ) . De novo design of picomolar SARS-CoV-2 miniprotein inhibitors . Science vol. 370 , ( 6515 )
Wang LT, Pereira LS, Flores-Garcia Y, O'Connor J, Flynn BJ, Schön A, Hurlburt NK, Dillon M et al. ( 2020 ) . A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver . Immunity vol. 53 , ( 4 ) 733 - 744.e8 .
Lajoie MJ, Boyken SE, Salter AI, Bruffey J, Rajan A, Langan RA, Olshefsky A, Muhunthan V et al. ( 2020 ) . Designed protein logic to target cells with precise combinations of surface antigens . Science vol. 369 , ( 6511 )
Kirkpatrick RL, Lewis K, Langan RA, Lajoie MJ, Boyken SE, Eakman M, Baker D, Zalatan JG ( 2020 ) . Conditional Recruitment to a DNA-Bound CRISPR-Cas Complex Using a Colocalization-Dependent Protein Switch . ACS Synthetic Biology vol. 9 , ( 9 ) 2316 - 2323 .
Basanta B, Bick MJ, Bera AK, Norn C, Chow CM, Carter LP, Goreshnik I, Dimaio F et al. ( 2020 ) . An enumerative algorithm for de novo design of proteins with diverse pocket structures . Proceedings of the National Academy of Sciences of the United States of America vol. 117 , ( 36 ) 22135 - 22145 .
Xu C, Lu P, Gamal El-Din TM, Pei XY, Johnson MC, Uyeda A, Bick MJ, Xu Q et al. ( 2020 ) . Computational design of transmembrane pores . Nature vol. 585 , ( 7823 ) 129 - 134 .
Rasheed F, Saeed M, Alikhan NF, Baker D, Khurshid M, Ainsworth EV, Turner AK, Imran AA et al. ( 2020 ) . Emergence of resistance to fluoroquinolones and third-generation cephalosporins in salmonella typhi in lahore, pakistan . Microorganisms vol. 8 , ( 9 ) 1 - 10 .
Petrova N, Nutma E, Carassiti D, RS Newman J, Amor S, Altmann DR, Baker D, Schmierer K ( 2020 ) . Synaptic Loss in Multiple Sclerosis Spinal Cord . Annals of Neurology vol. 88 , ( 3 ) 619 - 625 .
Jacobs B, Taylor T, Awad A, Baker D, Giovannoni G, Noyce A, Dobson R ( 2020 ) . Summary-data-based mendelian randomisation prioritises potential druggable targets for Multiple Sclerosis . Brain Communications
Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G et al. ( 2020 ) . COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases . Clinical and Experimental Immunology vol. 202 , ( 2 ) 149 - 161 .
Mateo-Casas M, Reyes S, O'Toole EA, De Trane S, Yildiz O, Allen-Philbey K, Mathews J, Baker D et al. ( 2020 ) . Severe skin reactions associated with cladribine in people with multiple sclerosis . Multiple Sclerosis and Related Disorders . vol. 43 ,
Antanasijevic A, Ueda G, Brouwer PJM, Copps J, Huang D, Allen JD, Cottrell CA, Yasmeen A et al. ( 2020 ) . Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens . PLoS Pathogens vol. 16 , ( 8 )
Ueda G, Antanasijevic A, Fallas JA, Sheffler W, Copps J, Ellis D, Hutchinson GB, Moyer A et al. ( 2020 ) . Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens . eLife vol. 9 , 1 - 30 .
Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G ( 2020 ) . The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic . Multiple Sclerosis and Related Disorders vol. 43 ,
Schmierer K, Baker D ( 2020 ) . B cells and multiple sclerosis spinal cord pathology . Brain Pathology vol. 30 , ( 4 ) 730 - 731 .
Saxena G, Moore JM, Jones M, Pryce G, Ali L, Leisegang GR, Vijay V, Loveless S et al. ( 2020 ) . Detecting and predicting neutralization of alemtuzumab responses in MS . Neurology(R) neuroimmunology & neuroinflammation vol. 7 , ( 4 )
Leman JK, Weitzner BD, Lewis SM, Adolf-Bryfogle J, Alam N, Alford RF, Aprahamian M, Baker D et al. ( 2020 ) . Macromolecular modeling and design in Rosetta: recent methods and frameworks . Nature Methods vol. 17 , ( 7 ) 665 - 680 .
Baker D ( 2020 ) . Enhanced axonal response of mitochondria to demyelination offers neuroprotection: implications for multiple sclerosis . Acta Neuropathologica
Amor S, Baker D, Khoury SJ, Schmierer K, Giovanonni G ( 2020 ) . SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad . Annals of Neurology vol. 87 , ( 6 ) 794 - 797 .
Baker D, Pryce G, James LK, Marta M, Schmierer K ( 2020 ) . The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis . Multiple Sclerosis and Related Disorders Article 102279 , 102279 - 102279 .
Leman JK, Weitzner BD, Renfrew PD, Lewis SM, Moretti R, Watkins AM, Mulligan VK, Lyskov S et al. ( 2020 ) . Better together: Elements of successful scientific software development in a distributed collaborative community . PLoS Computational Biology vol. 16 , ( 5 )
Brunette TJ, Bick MJ, Hansen JM, Chow CM, Kollman JM, Baker D ( 2020 ) . Modular repeat protein sculpting using rigid helical junctions . Proceedings of the National Academy of Sciences of the United States of America vol. 117 , ( 16 ) 8870 - 8875 .
Cannon KA, Park RU, Boyken SE, Nattermann U, Yi S, Baker D, King NP, Yeates TO ( 2020 ) . Design and structure of two new protein cages illustrate successes and ongoing challenges in protein engineering . Protein Science vol. 29 , ( 4 ) 919 - 929 .
Wei KY, Moschidi D, Bick MJ, Nerli S, McShan AC, Carter LP, Huang PS, Fletcher DA et al. ( 2020 ) . Computational design of closely related proteins that adopt two well-defined but structurally divergent folds . Proceedings of the National Academy of Sciences of the United States of America vol. 117 , ( 13 ) 7208 - 7215 .
Bertrand JA, Schicht M, Stamer WD, Baker D, Sherwood JM, Lütjen-Drecoll E, Selwood DL, Overby DR ( 2020 ) . The beta(4)-Subunit of the Large-Conductance Potassium Ion Channel K(Ca)1.1 Regulates Outflow Facility in Mice . Investigative Ophthalmology and Visual Science vol. 61 , ( 3 )
Ng AH, Nguyen TH, Gómez-Schiavon M, Dods G, Langan RA, Boyken SE, Samson JA, Waldburger LM et al. ( 2020 ) . Publisher Correction: Modular and tunable biological feedback control using a de novo protein switch (Nature, (2019), 572, 7768, (265-269), 10.1038/s41586-019-1425-7) . Nature vol. 579 , ( 7798 )
VanAernum ZL, Busch F, Jones BJ, Jia M, Chen Z, Boyken SE, Sahasrabuddhe A, Baker D et al. ( 2020 ) . Rapid online buffer exchange for screening of proteins, protein complexes and cell lysates by native mass spectrometry . Nature Protocols vol. 15 , ( 3 ) 1132 - 1157 .
Ali L, SAXENA G, Jones M, Leisegang G, Gammon L, Gnanapavan S, Giovannoni G, Schmierer K et al. ( 2020 ) . A cell-based assay for the detection of neutralizing antibodies against alemtuzumab . BioTechniques: the journal of laboratory technology for bioresearch
Baker D, Ali L, SAXENA G, Pryce G, Jones M, Schmierer K, Giovannoni G, Gnanapavan S et al. ( 2020 ) . The irony of humanization: Alemtuzumab the first, but one of the most immunogenic, humanized monoclonal antibodies . Frontiers in Immunology vol. 11 , ( 124 )
Saxena GK, Theocharopoulos I, Aziz NT, Jones M, Gnanapavan S, Giovannoni G, Schmierer K, Garnett JA et al. ( 2020 ) . GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains . Scientific Reports vol. 10 , ( 1 ) Article 1860 ,
Hellner B, Alamdari S, Pyles H, Zhang S, Prakash A, Sprenger KG, De Yoreo JJ, Baker D et al. ( 2020 ) . Sequence-Structure-Binding Relationships Reveal Adhesion Behavior of the Car9 Solid-Binding Peptide: An Integrated Experimental and Simulation Study . Journal of the American Chemical Society vol. 142 , ( 5 ) 2355 - 2363 .
Baker D, Pryce G, James LK, Schmierer K, Giovannoni G ( 2020 ) . Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis . European Journal of Neurology vol. 27 , ( 2 ) 221 - 228 .
Yang J, Anishchenko I, Park H, Peng Z, Ovchinnikov S, Baker D ( 2020 ) . Improved protein structure prediction using predicted interresidue orientations . Proceedings of the National Academy of Sciences of the United States of America vol. 117 , ( 3 ) 1496 - 1503 .
Baker D, Pryce G, James LK, Marta M, Schmierer K ( 2020 ) . The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis . Multiple Sclerosis and Related Disorders2020.01.09.20016774 - 2020.01.09.20016774 .
Farrell DP, Anishchenko I, Shakeel S, Lauko A, Passmore LA, Baker D, DiMaio F ( 2020 ) . Deep learning enables the atomic structure determination of the Fanconi Anemia core complex from cryoEM . IUCrJ vol. 7 , 881 - 892 .
Foster-Nyarko E, Alikhan NF, Ravi A, Thilliez G, Thomson NM, Baker D, Kay G, Cramer JD et al. ( 2020 ) . Genomic diversity of Escherichia coli isolates from non-human primates in the Gambia . Microbial Genomics vol. 6 , ( 9 ) 1 - 15 .
Yager P, Abe K, Anderson CE, Baker D, Belousov Y, Bishop J, Buser JR, Byrnes SA et al. ( 2020 ) . Low-cost disposable point-of-care devices based on porous materials for rapid detection of pathogens . 21st International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2017 . 97 - 100 .
Dou J, Goreshnik I, Bryan C, Baker D, Strauch EM ( 2020 ) . Parallelized identification of on- A nd off-target protein interactions . Molecular Systems Design and Engineering vol. 5 , ( 1 ) 349 - 357 .
Wu Q, Peng Z, Anishchenko I, Cong Q, Baker D, Yang J ( 2020 ) . Protein contact prediction using metagenome sequence data and residual neural networks . Bioinformatics vol. 36 , ( 1 ) 41 - 48 .
Yasir M, Keith Turner A, Bastkowski S, Baker D, Page AJ, Telatin A, Phan MD, Monahan L et al. ( 2020 ) . TRADIS-XPress: A high-resolution whole-genome assay identifies novel mechanisms of triclosan action and resistance . Genome Research vol. 30 , ( 2 ) 239 - 249 .
Yin Y, Ochi N, Craven TW, Baker D, Takigawa N, Suga H ( 2019 ) . De Novo Carborane-Containing Macrocyclic Peptides Targeting Human Epidermal Growth Factor Receptor . Journal of the American Chemical Society vol. 141 , ( 49 ) 19193 - 19197 .
Weitzner BD, Kipnis Y, Daniel AG, Hilvert D, Baker D ( 2019 ) . A computational method for design of connected catalytic networks in proteins . Protein Science vol. 28 , ( 12 ) 2036 - 2041 .
Valliere MA, Korman TP, Woodall NB, Khitrov GA, Taylor RE, Baker D, Bowie JU ( 2019 ) . Author Correction: A cell-free platform for the prenylation of natural products and application to cannabinoid production (Nature Communications, (2019), 10, 1, (565), 10.1038/s41467-019-08448-y) . Nature Communications vol. 10 , ( 1 )
Park J, Selvaraj B, McShan AC, Boyken SE, Wei KY, Oberdorfer G, Degrado W, Sgourakis NG et al. ( 2019 ) . De novo design of a homo-trimeric amantadine-binding protein . eLife vol. 8 ,
Brouwer PJM, Antanasijevic A, Berndsen Z, Yasmeen A, Fiala B, Bijl TPL, Bontjer I, Bale JB et al. ( 2019 ) . Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle . Nature Communications vol. 10 , ( 1 )
Park H, Lee GR, Kim DE, Anishchenko I, Cong Q, Baker D ( 2019 ) . High-accuracy refinement using Rosetta in CASP13 . Proteins: Structure, Function and Bioinformatics vol. 87 , ( 12 ) 1276 - 1282 .
Porter KA, Padhorny D, Desta I, Ignatov M, Beglov D, Kotelnikov S, Sun Z, Alekseenko A et al. ( 2019 ) . Template-based modeling by ClusPro in CASP13 and the potential for using co-evolutionary information in docking . Proteins: Structure, Function and Bioinformatics vol. 87 , ( 12 ) 1241 - 1248 .
Barros EP, Schiffer JM, Vorobieva A, Dou J, Baker D, Amaro RE ( 2019 ) . Improving the Efficiency of Ligand-Binding Protein Design with Molecular Dynamics Simulations . Journal of Chemical Theory and Computation vol. 15 , ( 10 ) 5703 - 5715 .
Farrell R, Baker D ( 2019 ) . An expert opinion: Optimisation of pharmacological management of multiple sclerosis related spasticity . Advances in Clinical Neuroscience and Rehabilitation vol. 18 , ( 5 ) 17 - 19 .
Foight GW, Wang Z, Wei CT, Greisen P, Warner KM, Cunningham-Bryant D, Park K, Brunette TJ et al. ( 2019 ) . Multi-input chemical control of protein dimerization for programming graded cellular responses . Nature Biotechnology vol. 37 , ( 10 ) 1209 - 1216 .
Baker D, Jacobs BM, Gnanapavan S, Schmierer K, Giovannoni G ( 2019 ) . Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 35 , 19 - 25 .
Tabatabaee S, Baker D, Selwood DL, Whalley BJ, Stephens GJ ( 2019 ) . The cannabinoid-like compound, vsn16r, acts on large conductance, ca<sup>2</sup>+-activated k<sup>+</sup> channels to modulate hippocampal ca1 pyramidal neuron firing . Pharmaceuticals vol. 12 , ( 3 )
Langan RA, Boyken SE, Ng AH, Samson JA, Dods G, Westbrook AM, Nguyen TH, Lajoie MJ et al. ( 2019 ) . De novo design of bioactive protein switches . Nature vol. 572 , ( 7768 ) 205 - 210 .
Ng AH, Nguyen TH, Gómez-Schiavon M, Dods G, Langan RA, Boyken SE, Samson JA, Waldburger LM et al. ( 2019 ) . Modular and tunable biological feedback control using a de novo protein switch . Nature vol. 572 , ( 7768 ) 265 - 269 .
Baker D, Amor S ( 2019 ) . Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model . Annals of Clinical and Translational Neurology
Pyles H, Zhang S, De Yoreo JJ, Baker D ( 2019 ) . Controlling protein assembly on inorganic crystals through designed protein interfaces . Nature vol. 571 , ( 7764 ) 251 - 256 .
Batcheller L, Baker D ( 2019 ) . Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer? . Journal of the Neurological Sciences vol. 404 , 19 - 28 .
Baker D ( 2019 ) . Computationally designed protein activation . National Science Review vol. 6 , ( 4 ) 609 - 610 .
Koepnick B, Flatten J, Husain T, Ford A, Silva DA, Bick MJ, Bauer A, Liu G et al. ( 2019 ) . De novo protein design by citizen scientists . Nature vol. 570 , ( 7761 ) 390 - 394 .
Bulutoglu B, Macazo FC, Bale J, King N, Baker D, Minteer SD, Banta S ( 2019 ) . Multimerization of an Alcohol Dehydrogenase by Fusion to a Designed Self-Assembling Protein Results in Enhanced Bioelectrocatalytic Operational Stability . ACS Applied Materials and Interfaces vol. 11 , ( 22 ) 20022 - 20028 .
Chen Z, Johnson MC, Chen J, Bick MJ, Boyken SE, Lin B, De Yoreo JJ, Kollman JM et al. ( 2019 ) . Self-Assembling 2D Arrays with de Novo Protein Building Blocks . Journal of the American Chemical Society vol. 141 , ( 22 ) 8891 - 8895 .
Dang LT, Miao Y, Ha A, Yuki K, Park K, Janda CY, Jude KM, Mohan K et al. ( 2019 ) . Receptor subtype discrimination using extensive shape complementary designed interfaces . Nature Structural and Molecular Biology vol. 26 , ( 6 ) 407 - 414 .
Cao L, Yu B, Kong D, Cong Q, Yu T, Chen Z, Hu Z, Chang H et al. ( 2019 ) . Functional expression and characterization of the envelope glycoprotein E1E2 heterodimer of hepatitis C virus . PLoS Pathogens vol. 15 , ( 5 )
Baker D, Pryce G, Herrod SS, Schmierer K ( 2019 ) . Potential mechanisms of action related to the efficacy and safety of cladribine . Multiple Sclerosis and Related Disorders vol. 30 , 176 - 186 .
Khatib F, Desfosses A, Players F, Koepnick B, Flatten J, Popović Z, Baker D, Cooper S et al. ( 2019 ) . Building de novo cryo-electron microscopy structures collaboratively with citizen scientists . PLoS Biology vol. 17 , ( 11 )
Pryce G, Baker D ( 2019 ) . CHAPTER 11 Cannabinoids as a Therapeutic Approach in Multiple Sclerosis . Emerging Drugs and Targets for Multiple Sclerosis ,
Pryce G, Baker D ( 2019 ) . CHAPTER 11: Cannabinoids as a Therapeutic Approach in Multiple Sclerosis . RSC Drug Discovery Series , vol. 2019-January ,
Snyder AG, Hubbard NW, Messmer MN, Kofman SB, Hagan CE, Orozco SL, Chiang K, Daniels BP et al. ( 2019 ) . Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity . Science Immunology vol. 4 , ( 36 )
Cong Q, Anishchenko I, Ovchinnikov S, Baker D ( 2019 ) . Protein interaction networks revealed by proteome coevolution . Science vol. 365 , ( 6449 ) 185 - 189 .
Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP et al. ( 2019 ) . Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies . Multiple Sclerosis and Related Disorders vol. 27 , 247 - 253 .
Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K ( 2018 ) . Cladribine: mechanisms and mysteries in multiple sclerosis . Journal of Neurology, Neurosurgery and Psychiatry vol. 89 , ( 12 ) 1266 - 1271 .
Dubuisson N, Marta M, Gnanapavan S, Turner B, Baker D, Thomson A, Schmierer K, Giovannoni G ( 2018 ) . Inclusion criteria used in trials of people with progressive multiple sclerosis . Mult Scler1352458518803769 - 1352458518803769 .
Maguire JB, Boyken SE, Baker D, Kuhlman B ( 2018 ) . Correction: Rapid sampling of hydrogen bond networks for computational protein design (Journal of Chemical Theory and Computation (2018) 14:5 (2751-2760) DOI: 10.1021/acs.jctc.8b00033) . Journal of Chemical Theory and Computation vol. 14 , ( 10 )
De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner BP et al. ( 2018 ) . Cladribine personalised dosing in people with MS (n > 200) - four years experience in clinical care .
Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al. ( 2018 ) . Elevated neurofilament light chain levels in progressive multiple sclerosis effectively reduced by cladribine treatment . MULTIPLE SCLEROSIS JOURNAL . vol. 24 , 949 - 949 .
Day AL, Greisen P, Doyle L, Schena A, Stella N, Johnsson K, Baker D, Stoddard B ( 2018 ) . Unintended specificity of an engineered ligand-binding protein facilitated by unpredicted plasticity of the protein fold . Protein Engineering, Design and Selection vol. 31 , ( 10 ) 375 - 387 .
BAKER D, GIOVANNONI G, PRYCE G, AMOR S, SCHMIERER K ( 2018 ) . Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis . Brain
BO XUENONG, GUSHCHINA S, PRYCE G, YIP P, WU D, PALLIER P, GIOVANNONI G, BAKER D ( 2018 ) . Increased expression of colony‐stimulating factor‐1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss . Glia vol. 66 , ( 10 ) 2108 - 2125 .
Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al. ( 2018 ) . Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine . Multiple Sclerosis and Related Disorders vol. 24 , 20 - 27 .
Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, Jin F, Fairley CK et al. ( 2018 ) . Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study . The Lancet HIV vol. 5 , ( 8 ) e438 - e447 .
BAKER D, Pryce, G ( 2018 ) . Oligoclonal bands in multiple sclerosis; functional significance and therapeutic implications. Does the specificity matter? . multiple sclerosis and related disorders
Mao Z, Álvarez-Gonzalez C, De Trane S, Yildiz O, Albor C, Doctor G, Soon D, Pepper G et al. ( 2018 ) . Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings? . Multiple Sclerosis Journal - Experimental, Translational and Clinical vol. 4 , ( 2 ) 2055217318783767 - 2055217318783767 .
Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S et al. ( 2018 ) . Alemtuzumab depletion failure can occur in multiple sclerosis . Immunology vol. 154 , ( 2 ) 253 - 260 .
Nicholson T, Church C, Baker DJ, Jones SW ( 2018 ) . The role of adipokines in skeletal muscle inflammation and insulin sensitivity . Journal of Inflammation (United Kingdom) vol. 15 , ( 1 )
Petrova N, Carassiti D, Altmann DR, Baker D, Schmierer K ( 2018 ) . Axonal loss in the multiple sclerosis spinal cord revisited . Brain Pathology vol. 28 , ( 3 ) 334 - 348 .
Ceronie B, Jacobs BM, Baker D, Dubuisson N, Mao Z, Ammoscato F, Lock H, Longhurst HJ et al. ( 2018 ) . Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells . Journal of Neurology vol. 265 , ( 5 ) 1199 - 1209 .
Ceronie B, Dubuisson N, Ammoscato F, Baker D, Giovannoni G, Schmierer K ( 2018 ) . Memory B Cells: Toward a Unified Therapeutic Target for Effective Immunotherapy in Multiple Sclerosis . NEUROLOGY . vol. 90 ,
Ruz-Maldonado I, Liu B, Atanes P, Pingitore A, Huang GC, Baker D, Persaud SJ ( 2018 ) . CB1 antagonists SR141617A and AM251 stimulate insulin secretion from mouse and human islets . DIABETIC MEDICINE . vol. 35 , 47 - 47 .
Biggs EK, Liang L, Naylor J, Madalli S, Collier R, Coghlan MP, Baker DJ, Hornigold DC et al. ( 2018 ) . Development and characterisation of a novel glucagon like peptide-1 receptor antibody . Diabetologia vol. 61 , ( 3 ) 711 - 721 .
Ruz-Maldonado I, Pingitore A, Liu B, Atanes P, Huang GC, Baker D, Alonso FJ, Bermúdez-Silva FJ et al. ( 2017 ) . LH‐21 and abnormal cannabidiol improve β‐cell function in isolated human and mouse islets through GPR55‐dependent and ‐independent signalling . Diabetes Obes Metab vol. 20 , ( 4 ) 930 - 942 .
Dubuisson N, Baker D, Thomson A, Marta M, Gnanapavan S, Turner B, Giovannoni G, Schmierer K ( 2017 ) . Disease modification in advanced MS: Focus on upper limb function . Multiple Sclerosis vol. 23 , ( 14 ) 1956 - 1957 .
Agez M, Schultz P, Medina I, Baker DJ, Burnham MP, Cardarelli RA, Conway LC, Garnier K et al. ( 2017 ) . Molecular architecture of potassium chloride co-transporter KCC2 . Scientific Reports vol. 7 , ( 1 )
Puentes F, van der Star BJ, Boomkamp SD, Kipp M, Boon L, Bosca I, Raffel J, Gnanapavan S et al. ( 2017 ) . Neurofilament light as an immune target for pathogenic antibodies . Immunology vol. 152 , ( 4 ) 580 - 588 .
Dubuisson N, Bauer A, Marta M, Gnanapavan S, Turner B, Baker D, Giovannoni G, Schmierer K et al. ( 2017 ) . PO124 Validation of an environmentally-friendly and affordable cardboard 9-hole peg test . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 ,
Schmierer K, Marta M, Pryce G, Giovannoni G, Baker D ( 2017 ) . PO150 Memory b cells are key for immunotherapy in multiple sclerosis . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 , a52 - a52 .
Pryce G, Baker D ( 2017 ) . Antidote to cannabinoid intoxication: the CB<inf>1</inf> receptor inverse agonist, AM251, reverses hypothermic effects of the CB<inf>1</inf> receptor agonist, CB-13, in mice . British Journal of Pharmacology vol. 174 , ( 21 ) 3790 - 3794 .
Baker D, Giovannoni G, Schmierer K ( 2017 ) . Marked neutropenia: significant but rare in people with multiple sclerosis after alemtuzumab treatment . Multiple Sclerosis and Related Disorders
Baker D, Kang AS, Gnanapavan S, Giovannoni G, Schmierer K ( 2017 ) . A central role of B cells in MS control and causing autoimmunity after alemtuzumab . MULTIPLE SCLEROSIS JOURNAL . vol. 23 , 336 - 336 .
Dubuisson N, Bauer A, Buckley M, Gilbert R, Paterson A, Marta M, Gnanapavan S, Turner B et al. ( 2017 ) . Validation of an environmentally-friendly and affordable cardboard 9-hole peg test . Multiple Sclerosis and Related Disorders vol. 17 , 172 - 176 .
BAKER D ( 2017 ) . SPATIAL DISTRIBUTION OF THE CANNABINOID TYPE 1 AND CAPSAICIN RECEPTORS MAY CONTRIBUTE TO THE COMPLEXITY OF THEIR CROSSTALK . Scientific Reports
Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K ( 2017 ) . Both cladribine and alemtuzumab may affect MS via B-cell depletion (vol 4, e360, 2017) . NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION vol. 4 , ( 5 )
Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K ( 2017 ) . Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab . JAMA Neurol vol. 74 , ( 8 ) 961 - 969 .
Afolabi D, Albor C, Zalewski L, Altmann DR, Baker D, Schmierer K ( 2017 ) . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis . Mult Scler1352458517726380 - 1352458517726380 .
BAKER D ( 2017 ) . Big conductance calcium-activated potassium channel openers control spasticity without sedation . British Journal of Pharmcology
BAKER D, SCHMIERER K, Herrod S, Alvarez Gonzalez C, Zalewski L, Albor C ( 2017 ) . Both cladribine and alemtuzumab may effect multiple sclerosis via B cell depletion . Neurology: Neuroimmunology and Neuroinflammation vol. 4 , ( 4 )
Alvarez-Gonzalez C, Adams A, Mathews J, Turner BP, Giovannoni G, Baker D, Schmierer K ( 2017 ) . Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis . Annals of Clinical and Translational Neurology
BAKER D, Giovannoni G, Sefia E, Pryce G, Meier U ( 2017 ) . Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis . Multiple Sclerosis and Related Disorders
Schmierer K, Herrod S, Alvarez-Gonzalez C, Baker D ( 2017 ) . Cladribine versus Alemtuzumab: efficacy and autoimmunity in multiple sclerosis induction treatment . NEUROLOGY . vol. 88 ,
Thomson A, Raciborska D, Baker D, Giovannoni G ( 2017 ) . How to start a blog . Pract Neurol vol. 17 , ( 3 ) 224 - 228 .
von Kutzleben S, Pryce G, Giovannoni G, Baker D ( 2017 ) . Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immunetolerance promoting CD8 t-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis . Immunology vol. 150 , ( 4 ) 444 - 455 .
Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K ( 2017 ) . Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis . EBioMedicine vol. 16 , 41 - 50 .
Giovannoni G, Cutter G, Pia-Sormani M, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D et al. ( 2017 ) . Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses . Multiple Sclerosis and Related Disorders vol. 12 , 70 - 78 .
Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K ( 2017 ) . Both cladribine and alemtuzumab may effect MS via B-cell depletion . Neurology: Neuroimmunology and NeuroInflammation vol. 4 , ( 4 )
Liu B, Song S, Ruz-Maldonado I, Pingitore A, Huang GC, Baker D, Jones PM, Persaud SJ ( 2016 ) . GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans . Diabetes, Obesity and Metabolism vol. 18 , ( 12 ) 1263 - 1273 .
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Turner BP, Baker D, Gnanapavan S, Marta M, Giovannoni G et al. ( 2016 ) . TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE . JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 87 ,
Williams T, Pryce G, Giovannoni G, Selwood D, Baker D ( 2016 ) . VSN16R-A NOVEL TREATMENT FOR SPASTICITY IN EXPERIMENTAL MULTIPLE SCLEROSIS . vol. 87 , is. 12 , Abstract: java.sql.Clob org.hibernate.engine.jdbc.WrappedClob java.io.Serializable ,
Baker D, Anandhakrishnan A, Tuite-Dalton KA, Lockart–Jones H, Middleton RM, Ford DV, Crowe C, Giovannoni G ( 2016 ) . How to refer to people with disease in research outputs: The disconnection between academic practise and that preferred by people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 10 , 127 - 133 .
Peferoen LAN, Breur M, van de Berg S, Peferoen-Baert R, Boddeke EHWGM, van der Valk P, Pryce G, van Noort JM et al. ( 2016 ) . Ageing and recurrent episodes of neuroinflammation promote progressive experimental autoimmune encephalomyelitis in Biozzi ABH mice . Immunology vol. 149 , ( 2 ) 146 - 156 .
Horowitz S, Koepnick B, Martin R, Tymieniecki A, Winburn AA, Cooper S, Flatten J, Rogawski DS et al. ( 2016 ) . Determining crystal structures through crowdsourcing and coursework . Nature Communications vol. 7 ,
Burnham SC, Rowe CC, Baker D, Bush AI, Doecke JD, Faux NG, Laws SM, Martins RN et al. ( 2016 ) . Predicting Alzheimer disease from a blood-based biomarker profile . Neurology vol. 87 , ( 11 ) 1093 - 1101 .
Park H, DiMaio F, Baker D ( 2016 ) . CASP11 refinement experiments with ROSETTA . Proteins: Structure, Function and Bioinformatics vol. 84 , ( S1 ) 314 - 322 .
Agahozo MC, Peferoen L, Baker D, Amor S ( 2016 ) . CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis – Targeting T or B cells? . Multiple Sclerosis and Related Disorders vol. 9 , Article C , 110 - 117 .
Thomson A, Giovannoni G, Marta M, Gnanpavan S, Turner B, Baker D, Schmierer K ( 2016 ) . Importance of upper limb function in advanced multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 676 - 676 .
Rejdak K, Mitosek-Szewczyk K, Prus K, Trzciniecka O, Baker D, Schmierer K, Stelmasiak Z ( 2016 ) . Induction therapy of relapsing secondary multiple sclerosis using generic cladribine . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 593 - 594 .
Petrova N, Carassiti D, Scaravilli F, Baker D, Schmierer K ( 2016 ) . Synaptic loss in the MS spinal cord: a key driver of disease progression? . MULTIPLE SCLEROSIS JOURNAL . Conference: ECTRIMS 2016 Committees ( UCL Institute of Neurology, London, UK ) from: 14/09/2016 to: 17/09/2016 , vol. 22 , 80 - 80 .
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Espasandin M, Turner BP, Gnanapavan S, Marta M, Giovannoni G et al. ( 2016 ) . Treating multiple sclerosis with generic cladribine . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) vol. 22 , 604 - 605 .
Baird AL, Hye A, Westwood S, Ashton NJ, Liu BY, Bazenet C, Kiddle SJ, Ward M et al. ( 2016 ) . S4‐01‐01: Cross‐Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau . Alzheimer's & Dementia vol. 12 , ( 7S_Part_6 ) p321 - p321 .
Sevastou I, Pryce G, Baker D, Selwood DL ( 2016 ) . Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA Sequencing . PLOS ONE vol. 11 , ( 6 ) e0157754 - e0157754 .
Ummenthum K, Peferoen LAN, Finardi A, Baker D, Pryce G, Mantovani A, Bsibsi M, Bottazzi B et al. ( 2016 ) . Pentraxin-3 is upregulated in the central nervous system during MS and EAE, but does not modulate experimental neurological disease . European Journal of Immunology vol. 46 , ( 3 ) 701 - 711 .
Warne J, Pryce G, Hill JM, Shi X, Lennerås F, Puentes F, Kip M, Hilditch L et al. ( 2016 ) . Selective inhibition of the mitochondrial permeability transition pore protects against neurodegeneration in experimental multiple sclerosis . Journal of Biological Chemistry vol. 291 , ( 9 ) 4356 - 4373 .
Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D ( 2015 ) . Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids . Journal of Neuroimmune Pharmacology vol. 10 , ( 2 ) 281 - 292 .
Pryce G, Baker D ( 2015 ) . Endocannabinoids in multiple sclerosis and amyotrophic lateral sclerosis . vol. 231 , 213 - 231 .
Leung YY, Toledo JB, Nefedov A, Polikar R, Raghavan N, Xie SX, Farnum M, Schultz T et al. ( 2015 ) . Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study . Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring vol. 1 , ( 3 ) 339 - 348 .
Ruz Maldonado I, Pingitore A, Liu B, Huang GC, Baker D, Bermudez-Silva FJ, Persaud SJ ( 2015 ) . Stimulation of insulin secretion by cannabinoid ligands LH-21 and Abn-CBD in mouse and human islets: evaluation of the role of GPR55 . DIABETOLOGIA . vol. 58 , S86 - S86 .
Pryce G, Baker D ( 2015 ) . Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis . Evidence-Based Medicine vol. 20 , ( 4 )
Spellman DS, Wildsmith KR, Honigberg LA, Tuefferd M, Baker D, Raghavan N, Nairn AC, Croteau P et al. ( 2015 ) . Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF . Proteomics - Clinical Applications vol. 9 , ( 7-8 ) 715 - 731 .
Vainchtein I, Vinet J, Al-Izki S, Pryce G, Grit C, Brouwer N, Amor S, Baker D et al. ( 2015 ) . Microglia are involved in apoptotic clearance during chronic-relapsing EAE . GLIA . vol. 63 , E353 - E353 .
Raghavan N, Ard MC, Baker D, Narayan VA, Edland S, Team TAR ( 2015 ) . P3‐308: The adcs‐pacc composite endpoint: An assessment of sample size efficiencies in the aibl study of aging using optimally weighted components . Alzheimer's & Dementia vol. 11 , ( 7S_Part_16 ) p755 - p755 .
Budgeon CA, Murray K, Turlach BA, Baker D, Villemagne VL, Burnham S ( 2015 ) . P4‐228: Techniques for assessing Alzheimer's disease progression . Alzheimer's & Dementia vol. 11 , ( 7S_Part_19 ) p867 - p868 .
Voyle N, Baker D, Burnham SC, Covin A, Zhang Z, Sangurdekar DP, Tan Hehir CA, Bazenet C et al. ( 2015 ) . Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology . Journal of Alzheimer's Disease vol. 46 , ( 4 ) 947 - 961 .
Burnham SC, Raghavan N, Wilson W, Baker D, Ropacki MT, Novak G, Ames D, Ellis K et al. ( 2015 ) . Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study . Journal of Alzheimer's Disease vol. 46 , ( 4 ) 1079 - 1089 .
Ramaglia V, Jackson SJ, Hughes TR, Neal JW, Baker D, Morgan BP ( 2015 ) . Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse . Clinical and Experimental Immunology vol. 180 , ( 3 ) 432 - 441 .
Waring MJ, Baker DJ, Bennett SNL, Dossetter AG, Fenwick M, Garcia R, Georgsson J, Groombridge SD et al. ( 2015 ) . Discovery of a series of 2-(pyridinyl)pyrimidines as potent antagonists of GPR40 . MedChemComm vol. 6 , ( 6 ) 1024 - 1029 .
Baker D, Amora S ( 2015 ) . Mouse models of multiple sclerosis: Lost in translation? . Current Pharmaceutical Design vol. 21 , ( 18 ) 2440 - 2452 .
Browne L, Lidster K, Al-Izki S, Clutterbuck L, Posada C, Chan AWE, Riddall D, Garthwaite J et al. ( 2015 ) . Erratum: Correction to imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis (Journal of Medicinal Chemistry (2014) 57: 2942-2952 DOI: 10.1021/jm401881q) . Journal of Medicinal Chemistry vol. 58 , ( 8 )
Wu D, Cerutti C, Lopez-Ramirez MA, Pryce G, King-Robson J, Simpson JE, Van Der Pol SMA, Hirst MC et al. ( 2015 ) . Brain endothelial miR-146a negatively modulates T-cell adhesion through repressing multiple targets to inhibit NF-κB activation . Journal of Cerebral Blood Flow and Metabolism vol. 35 , ( 3 ) 412 - 423 .
Biela A, Watkinson M, Meier UC, Baker D, Giovannoni G, Becer CR, Krause S ( 2015 ) . Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy . Biosensors and Bioelectronics vol. 68 , 660 - 667 .
Ashton NJ, Kiddle SJ, Graf J, Ward M, Baird AL, Hye A, Westwood S, Wong KV et al. ( 2015 ) . Blood protein predictors of brain amyloid for enrichment in clinical trials? . Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring vol. 1 , ( 1 ) 48 - 60 .
Wu D, Cerutti C, Lopez-Ramirez MA, Pryce G, King-Robson J, Simpson JE, Van Der Pol SMA, Hirst MC et al. ( 2015 ) . Brain endothelial miR-146a negatively modulates T-cell adhesion through repressing multiple targets to inhibit NF-κB activation . Journal of Perinatology vol. 35 , ( 3 ) 412 - 423 .
Ramaglia V, Jackson SJ, Hughes TR, Neal JW, Baker D, Morgan BP ( 2015 ) . Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse . Clinical and Experimental Immunology
Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D et al. ( 2015 ) . No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine . Neurology: Neuroimmunology and NeuroInflammation vol. 2 , ( 6 )
Giovannoni G, Baker D, Schmierer K ( 2015 ) . The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis? . Multiple Sclerosis and Related Disorders vol. 4 , ( 1 ) 3 - 5 .
Von Kutzleben S, Pryce G, Chretien N, Turner M, Siders W, Baker D ( 2014 ) . Inhibition of relapsing experimental autoimmune encephalomyelitis in Biozzi ABH mice using a mouse CD52-specific monoclonal antibody . Journal of Neuroimmunology . vol. 275 ,
Giovannoni G, Baker D, Schmierer K ( 2014 ) . Simvastatin in patients with progressive multiple sclerosis . Lancet vol. 384 , ( 9947 )
Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner B, Calado-Marta M, Juliusson G, Baker D et al. ( 2014 ) . CANCER RISK IN MULTIPLE SCLEROSIS PATIENTS TAKING CLADRIBINE . Journal of Neurology Neurosurgery & Psychiatry . vol. 85 , e4 - e4 .
Pakpoor J, Nyein S, Disanto G, Nwosu A, Baker D, Giovannoni G ( 2014 ) . A global analysis of the use of social media to discuss multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL . vol. 20 , 334 - 335 .
Liu B, Song S, Baker D, Hassan Z, Drynda RL, Bowe JE, Jones PM, Persaud SJ ( 2014 ) . Knockout of GPR55 impairs insulin secretion and reduces islet cell turnover . DIABETOLOGIA vol. 57 , S49 - S49 .
Amor S, van der Star BJ, Bosca I, Raffel J, Gnanapavan S, Watchorn J, Kuhle J, Giovannoni G et al. ( 2014 ) . Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis . Mult Scler vol. 20 , ( 10 ) 1355 - 1362 .
Ashton NJ, Hye A, Baird A, Torres A, Covin A, Bazenet C, Tan‐Hehir C, Baker D et al. ( 2014 ) . F5‐02‐02: DISTINCT BLOOD PROTEIN MARKERS ARE ASSOCIATED WITH GLOBAL AND REGIONAL BRAIN BETA‐AMYLOID DEPOSITION IN ALZHEIMER'S DISEASE . Alzheimer's & Dementia vol. 10 , ( 4S_Part_5 ) p283 - p283 .
Burnham SC, Ames D, Baker D, Bush AI, Cobiac L, Doecke J, Ellis KA, Faux NG et al. ( 2014 ) . O2‐13‐06: PREDICTING ALZHEIMER'S DISEASE FROM A BLOOD‐BASED BIOMARKER PROFILE: RESULTS FROM AIPL AT 54 MONTHS . Alzheimer's & Dementia vol. 10 , ( 4S_Part_3 ) p196 - p196 .
Ashton NJ, Kiddle SJ, Thurfjell L, Graf J, Ward M, Baird AL, Hye A, Dobson RJ et al. ( 2014 ) . P1‐166: DISTINCT BLOOD PROTEIN MARKERS ARE ASSOCIATED WITH BRAIN REGIONS OF EARLY AMYLOID DEPOSITION IN ALZHEIMER'S DISEASE . Alzheimer's & Dementia vol. 10 , ( 4S_Part_9 ) p360 - p361 .
Burnham S, Raghavan N, Wilson B, Baker D, Ropacki MT, Novak G, Ames D, Ellis KA et al. ( 2014 ) . P2‐250: NOVEL STATISTICALLY‐DERIVED COMPOSITE MEASURES FOR ASSESSING THE EFFICACY OF DISEASE‐MODIFYING THERAPIES IN PRODROMAL AD TRIALS: AN AIPL STUDY . Alzheimer's & Dementia vol. 10 , ( 4S_Part_14 ) p567 - p567 .
Giovannoni G, Baker D, Schmierer K ( 2014 ) . The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis? . Multiple Sclerosis and Related Disorders
Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE, Reijerkerk A, King-Robson J, Kay O, de Vries HE et al. ( 2014 ) . MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation . FASEB J vol. 28 , ( 6 ) 2551 - 2565 .
Browne L, Lidster K, Al-Izki S, Clutterbuck L, Posada C, Chan AWE, Riddall D, Garthwaite J et al. ( 2014 ) . Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis . J Med Chem vol. 57 , ( 7 ) 2942 - 2952 .
Baker DJ, Atkinson AM, Wilkinson GP, Coope GJ, Charles AD, Leighton B ( 2014 ) . Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes . British Journal of Pharmacology vol. 171 , ( 7 ) 1629 - 1641 .
Baker DJ, Wilkinson GP, Atkinson AM, Jones HB, Coghlan M, Charles AD, Leighton B ( 2014 ) . Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes . British Journal of Pharmacology vol. 171 , ( 7 ) 1642 - 1654 .
Liu B, Song S, Baker D, Hassan Z, Drynda RL, Bowe JE, Jones PM, Persaud SJ ( 2014 ) . GPR55 deletion is coupled to impaired insulin secretion and reduced islet cell turnover . DIABETIC MEDICINE vol. 31 , 9 - 9 .
Puentes F, Topping J, Kuhle J, van der Star BJ, Douiri A, Giovannoni G, Baker D, Amor S et al. ( 2014 ) . Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis . J Neurol Neurosurg Psychiatry vol. 85 , ( 3 ) 274 - 278 .
Song S, Liu B, Bowe JE, Baker D, Jones PM, Persaud SJ ( 2014 ) . Specificity of GPR55 agonists and antagonist in the regulation of calcium handling and insulin secretion by mouse islets . DIABETIC MEDICINE vol. 31 , 32 - 32 .
Van Den Elsen PJ, Van Eggermond MCJA, Puentes F, Van Der Valk P, Baker D, Amor S ( 2014 ) . The epigenetics of multiple sclerosis and other related disorders . Multiple Sclerosis and Related Disorders vol. 3 , ( 2 ) 163 - 175 .
Dua P, Warnes G, Chruch A, Martino D, Baker D, Giovannoni G, Meier UC ( 2014 ) . Functional effects of anti-neuronal antibodies from patients with Tourette's syndrome and disorders associated with streptococcal infection . Neurology Psychiatry and Brain Research vol. 20 , ( 1 ) 17 - 18 .
Whyte L, Khalid A, Finnie G, Chiu S, Baker D, Aspden R, Ross R ( 2014 ) . GPR55 Regulates Peak Bone Mass and Steroid Hormone Levels in Male Mice . JOURNAL OF BONE AND MINERAL RESEARCH . vol. 29 , S409 - S409 .
Hampton DW, Serio A, Pryce G, Al-Izki S, Franklin RJM, Giovannoni G, Baker D, Chandran S ( 2014 ) . Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis . Acta Neuropathologica Communications vol. 2 , ( 1 )
Pryce G, Visintin C, Ramagopalan SV, Al-Izki S, De Faveri LE, Nuamah RA, Mein CA, Montpetit A et al. ( 2014 ) . Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists . FASEB J vol. 28 , ( 1 ) 117 - 130 .
Baker D, Amor S ( 2014 ) . Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely . Multiple Sclerosis and Related Disorders
Baker D, Pell C, Donovan B ( 2014 ) . HIV infection as a chronic disease: Optimising outcomes . Medicine Today vol. 15 , ( 2 ) 16 - 26 .
Amor S, Peferoen LAN, Vogel DYS, Breur M, van der Valk P, Baker D, Van Noort JM ( 2014 ) . Inflammation in neurodegenerative diseases - an update . Immunology vol. 142 , ( 2 ) 151 - 166 .
Mullen L, Rigby A, Sclanders M, Adams G, Mittal G, Colston J, Fatah R, Subang C et al. ( 2014 ) . Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β . Expert Opin Drug Deliv vol. 11 , ( 1 ) 5 - 16 .
Mullen L, Adams G, Layward L, Vessillier S, Annenkov A, Mittal G, Rigby A, Sclanders M et al. ( 2014 ) . Latent cytokines for targeted therapy of inflammatory disorders . Expert Opin Drug Deliv vol. 11 , ( 1 ) 101 - 110 .
Al-Izki S, Pryce G, Hankey DJR, Lidster K, von Kutzleben SM, Browne L, Clutterbuck L, Posada C et al. ( 2014 ) . Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis . Brain vol. 137 , ( Pt 1 ) 92 - 108 .
Baker D, Pepper G, Yauner F, Giovannoni G ( 2014 ) . MSer - A new, neutral descriptor for someone with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 3 , ( 1 ) 31 - 33 .
Baker D, Lidster K, Sottomayor A, Amor S ( 2014 ) . Two years later: journals are not yet enforcing the ARRIVE guidelines on reporting standards for pre-clinical animal studies . PLoS Biol vol. 12 , ( 1 )
Pryce G, Cabranes A, Fernández-Ruiz J, Bisogno T, Di Marzo V, Long JZ, Cravatt BF, Giovannoni G et al. ( 2013 ) . Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors . Mult Scler vol. 19 , ( 14 ) 1896 - 1904 .
Delarasse C, Smith P, Baker D, Amor S ( 2013 ) . Novel pathogenic epitopes of myelin oligodendrocyte glycoprotein induce experimental autoimmune encephalomyelitis in C57BL/6 mice . Immunology vol. 140 , ( 4 ) 456 - 464 .
James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV ( 2013 ) . The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis . Mult Scler vol. 19 , ( 12 ) 1571 - 1579 .
Puentes F, van der Star BJ, Victor M, Kipp M, Beyer C, Peferoen-Baert R, Ummenthum K, Pryce G et al. ( 2013 ) . Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis . Journal of Neuroinflammation vol. 10 ,
Liu B, Song S, Baker D, Bowe J, Hassan Z, Drynda R, Jones P, Persaud S ( 2013 ) . GPR55 deletion is coupled to impaired glucose tolerance and increased islet cell apoptosis . DIABETOLOGIA . vol. 56 , S46 - S46 .
Richter F, Baker D ( 2013 ) . Computational protein design for synthetic biology . Synthetic Biology: Tools and Applications ,
Di Filippo M, Chiasserini D, Gardoni F, Viviani B, Tozzi A, Giampa C, Costa C, Tantucci M et al. ( 2013 ) . Effects of central and peripheral inflammation on hippocampal synaptic plasticity . NEUROBIOLOGY OF DISEASE vol. 52 , 229 - 236 .
Baker D, Lidster K, Al-Izki S, Pryce G, Giovannoni G ( 2013 ) . Animal models of progressive disability in MS . IRISH JOURNAL OF MEDICAL SCIENCE vol. 182 , S5 - S6 .
Sisay S, Pryce G, Jackson SJ, Tanner C, Ross RA, Michael GJ, Selwood DL, Giovannoni G et al. ( 2013 ) . Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis . PLoS One vol. 8 , ( 10 )
Baker D, Pepper G, Yauner F, Giovannoni G ( 2013 ) . MSer - A new, neutral descriptor for someone with multiple sclerosis . Multiple Sclerosis and Related Disorders
Lidster K, Jackson SJ, Ahmed Z, Munro P, Coffey P, Giovannoni G, Baker MD, Baker D ( 2013 ) . Neuroprotection in a novel mouse model of multiple sclerosis . PLoS One vol. 8 , ( 11 )
van den Elsen PJ, van Eggermond MCJA, Puentes F, van der Valk P, Baker D, Amor S ( 2013 ) . The epigenetics of multiple sclerosis and other related disorders . Multiple Sclerosis and Related Disorders
Khoury GA, Liwo A, Khatib F, Zhou H, Chopra G, Bacardit J, Bortot LO, Faccioli RA et al. ( 2013 ) . Wefold: A collaborative protein structure prediction experiment . Computational Molecular Science and Engineering Forum 2013 - Core Programming Area at the 2013 AIChE Annual Meeting: Global Challenges for Engineering a Sustainable Future . 182 - 184 .
Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE, Reijerkerk A, King-Robson J, de Vries HE, Hirst MC et al. ( 2012 ) . Endothelial miR-155 promotes blood brain barrier dysfunction in neuroinflammation . JOURNAL OF NEUROIMMUNOLOGY . vol. 253 , 3 - 4 .
van der Star B, Puentes F, Gerritsen W, Huizinga R, Reijerkerk A, van der Valk P, Baker D, Amor S ( 2012 ) . Neuronal specific T cells are pathogenic in Biozzi mice - Implications for MS . JOURNAL OF NEUROIMMUNOLOGY . vol. 253 , 155 - 155 .
Baker D, Lidster K, Sottomayor A, Amor S ( 2012 ) . Reproducibility: Research-reporting standards fall short . Nature vol. 492 , ( 7427 )
Baker D, Lidster K, Sottomayor A, Amor S ( 2012 ) . Reproducibility: Research-reporting standards fall short . Nature vol. 492 , ( 7427 )
Fox RJ, Thompson A, Baker D, Baneke P, Brown D, Browne P, Chandraratna D, Ciccarelli O et al. ( 2012 ) . Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS . MULTIPLE SCLEROSIS JOURNAL vol. 18 , ( 11 ) 1534 - 1540 .
Song S, Liu B, Baker D, Huang GC, Amiel SA, King AJ, Bowe JE, Jones PM et al. ( 2012 ) . Islet GPR55 is coupled to increased insulin secretion and decreased apoptosis . DIABETOLOGIA vol. 55 , S163 - S163 .
Li C, Bowe JE, Baker D, Jones PM, Persaud SJ ( 2012 ) . PS 014 Beta cell GPCRs and other signalling mechanisms . DIABETOLOGIA vol. 55 , S163 - S163 .
van der Star BJ, Vogel DYS, Kipp M, Puentes F, Baker D, Amor S ( 2012 ) . In Vitro and In Vivo Models of Multiple Sclerosis . CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS vol. 11 , ( 5 ) 570 - 588 .
van Noort JM, Baker D, Amor S ( 2012 ) . Mechanisms in the Development of Multiple Sclerosis Lesions: Reconciling Autoimmune and Neurodegenerative Factors . CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS vol. 11 , ( 5 ) 556 - 569 .
Baker D, Amor S ( 2012 ) . Multiple sclerosis - from bench to bedside . CNS Neurol Disord Drug Targets vol. 11 , ( 5 ) 495 - 496 .
Lidster K, Baker D ( 2012 ) . Optical coherence tomography detection of neurodegeneration in multiple sclerosis . CNS Neurol Disord Drug Targets vol. 11 , ( 5 ) 518 - 527 .
Pryce G, Baker D ( 2012 ) . Potential control of multiple sclerosis by cannabis and the endocannabinoid system . CNS Neurol Disord Drug Targets vol. 11 , ( 5 ) 624 - 641 .
Amor S, Baker D ( 2012 ) . Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders . Multiple Sclerosis and Related Disorders vol. 1 , ( 3 ) 111 - 115 .
Gnanapavan S, Grant D, Pryce G, Jackson S, Baker D, Giovannoni G ( 2012 ) . Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis . Autoimmunity vol. 45 , ( 4 ) 298 - 303 .
Baker D, Pryce G, Jackson SJ, Bolton C, Giovannoni G ( 2012 ) . The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 1 , ( 2 ) 64 - 75 .
Dua P, Meier UC, Baker D, Giovannoni G ( 2012 ) . Functional effects of anti-neuronal antibodies in patients with encephalitis lethargica and other related disorders associated with streptococcal infection . Neurology Psychiatry and Brain Research vol. 18 , ( 2 )
Baker D, Amor S ( 2012 ) . Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis . J Neuroimmunol vol. 242 , ( 1-2 ) 78 - 83 .
Kipp M, Van Der Star B, Vogel DYS, Puentes F, Van Der Valk P, Baker D, Amor S ( 2012 ) . Experimental in vivo and in vitro models of multiple sclerosis: EAE and beyond . Multiple Sclerosis and Related Disorders vol. 1 , ( 1 ) 15 - 28 .
Sher F, Amor S, Gerritsen W, Baker D, Jackson SL, Boddeke E, Copray S ( 2012 ) . Intraventricularly Injected Olig2-NSCs Attenuate Established Relapsing-Remitting EAE in Mice . CELL TRANSPLANTATION vol. 21 , ( 9 ) 1883 - 1897 .
Al-Izki S, Pryce G, O'Neill JK, Butter C, Giovannoni G, Amor S, Baker D ( 2012 ) . Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse . Multiple Sclerosis and Related Disorders vol. 1 , ( 1 ) 29 - 38 .
Puentes F, van der Star B, Huizinga R, Gerritsen W, van der Valk P, Baker D, Amor S ( 2011 ) . Autoimmunity to axonal proteins in multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S329 - S329 .
Jackson S, Giovannoni G, Baker D ( 2011 ) . Fingolimod (FTY720) modulates microglial activation to augment markers of remyelination . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S210 - S210 .
Lidster K, Jackson S, Coffey P, Baker M, Garthwaite J, Selwood D, Giovannoni G, Baker D ( 2011 ) . Neuroprotection in a novel optic neuritis model . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S435 - S435 .
Al-Izki S, Pryce G, Amor S, Gerritsen W, Garthwaite J, Giovannoni G, Selwood DL, Baker D ( 2011 ) . Selective targeting of neuroprotection to MS lesions: sodium channel blockers in experimental autoimmune encephalomyelitis . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S209 - S210 .
Pryce G, Visintin C, Lutz B, Marsicano G, Giovannoni G, Selwood DL, Baker D ( 2011 ) . Selective targeting of spasticity by CNS-excluded cannabinoids . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S247 - S247 .
Baker D, Pryce G, Visintin C, Pertwee RG, Tanner C, Ross R, Irving A, Sisay S et al. ( 2011 ) . VSN16R a novel agent for the control of spasticity . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S243 - S243 .
Ayoub SS, Pryce G, Seed MP, Bolton C, Flower RJ, Baker D ( 2011 ) . Paracetamol-induced hypothermia is independent of cannabinoids and transient receptor potential vanilloid-1 and is not mediated by AM404 . Drug Metab Dispos vol. 39 , ( 9 ) 1689 - 1695 .
Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D ( 2011 ) . Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis . Mult Scler vol. 17 , ( 8 ) 939 - 948 .
Jackson SJ, Giovannoni G, Baker D ( 2011 ) . Fingolimod modulates microglial activation to augment markers of remyelination . J Neuroinflammation vol. 8 ,
Andreou AP, Supronsinchai W, Lasalandra M, Baker D, Goadsby PJ ( 2011 ) . Cannabinoid mechanisms of acetaminophen within the trigeminal thalamus . CEPHALALGIA . vol. 31 , 8 - 8 .
Baker D, Gerritsen W, Rundle J, Amor S ( 2011 ) . Critical appraisal of animal models of multiple sclerosis . Mult Scler vol. 17 , ( 6 ) 647 - 657 .
Baker D, Amor S ( 2010 ) . Editorial: Quality control of experimental autoimmune encephalomyelitis . Multiple Sclerosis vol. 16 , ( 9 ) 1025 - 1027 .
Baker D, Amor S ( 2010 ) . Quality control of experimental autoimmune encephalomyelitis . Mult Scler vol. 16 , ( 9 ) 1025 - 1027 .
Amor S, Puentes F, Baker D, van der Valk P ( 2010 ) . Inflammation in neurodegenerative diseases . IMMUNOLOGY vol. 129 , ( 2 ) 154 - 169 .
Idris AI, Sophocleous A, Landao-Bassonga E, Canals M, Milligan G, Baker D, van't Hof RJ, Ralston SH ( 2009 ) . Cannabinoid Receptor Type 1 Protects against Age-Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells . CELL METAB vol. 10 , ( 2 ) 139 - 147 .
Al-Izki S, Pryce G, Giovannoni G, Baker D ( 2009 ) . Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography . Mult Scler vol. 15 , ( 7 ) 795 - 801 .
Idris AI, Sophocleous A, Landao-Bassonga E, Merkouris M, Milligan GI, Baker D, van't Hof RJ, Ralston SH ( 2009 ) . Cannabinoid receptor type 1 protects against age-related bone loss by regulating osteoblast and adipocyte differentiation of bone marrow stromal cells . BONE . vol. 44 , S222 - S222 .
Hooper C, Pinteaux-Jones F, Fry VA, Sevastou IG, BAKER D, Heales SJ, Pocock JM ( 2009 ) . Differential effects of albumin on microglia and macrophages; implications for neurodegeneration following blood-brain barrier damage . J Neurochem vol. 109 , ( 3 ) 694 - 705 .
Amor S, Baker D ( 2009 ) . Experimental autoimmune encephalomyelitis . The Biology of Multiple Sclerosis ,
Rigby A, Baker D, Chernajovsky Y ( 2008 ) . Targeting EPO to the CNS; development of a novel therapeutic strategy . IMMUNOLOGY . vol. 125 , 134 - 135 .
Hampton DW, Anderson J, Pryce G, Irvine KA, Giovannoni G, Fawcett JW, Compston A, Franklin RJM et al. ( 2008 ) . An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss . J NEUROIMMUNOL vol. 201 , 200 - 211 .
Jackson S, Al-Izik S, Pryce G, Giovannoni G, Baker D ( 2008 ) . Fingolimod reduces axonal loss in relapsing secondary progressive experimental autoimmune encephalomyelitis . MULTIPLE SCLEROSIS . vol. 14 , S80 - S81 .
Parkes H, Shorter S, So PW, Baker D, Pryce G, Giovannoni G, Schmierer K ( 2008 ) . High resolution 1H nuclear magnetic resonance spectroscopic-based metabolomic urine analysis of experimental autoimmune encephalitis, a model disease of multiple sclerosis . MULTIPLE SCLEROSIS . vol. 14 , S86 - S87 .
Al-Izki S, Pryce G, Jackson S, Giovannoni G, Baker D ( 2008 ) . Neuroprotective effects of omega-3 fatty acids in a mouse model of multiple sclerosis . JOURNAL OF NEUROIMMUNOLOGY . vol. 197 , 173 - 173 .
Rigby A, Chernajovsky Y, Baker D ( 2008 ) . Targeting EPO to the CNS; Development of a novel therapeutic strategy . JOURNAL OF NEUROIMMUNOLOGY . vol. 197 , 171 - 171 .
Anderson JM, Hampton DW, Patani R, Pryce G, Crowther RA, Reynolds R, Franklin RJM, Giovannoni G et al. ( 2008 ) . Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis . BRAIN vol. 131 , 1736 - 1748 .
Pinteaux-Jones F, Sevastou IG, Fry VAH, Heales S, Baker D, Pocock JM ( 2008 ) . Myelin-induced microglial neurotoxicity can be controlled by microglial metabotropic glutamate receptors . J NEUROCHEM vol. 106 , ( 1 ) 442 - 454 .
East E, Gverić D, Baker D, Pryce G, Lijnen HR, Cuzner ML ( 2008 ) . Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation . Neuropathol Appl Neurobiol vol. 34 , ( 2 ) 216 - 230 .
Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker D ( 2008 ) . Cannabinoid-mediated neuroprotection, not immuno suppression, may be more relevant to multiple sclerosis . J NEUROIMMUNOL vol. 193 , ( 1-2 ) 120 - 129 .
Pryce G, Jackson SJ, Baker D ( 2008 ) . Cannabinoids for the control of multiple sclerosis . Cannabinoids and the Brain ,
Betik AC, Baker DJ, Krause DJ, McConkey MJ, Hepple RT ( 2008 ) . Exercise training in late middle-aged male Fischer 344 x Brown Norway F1-hybrid rats improves skeletal muscle aerobic function . Experimental Physiology vol. 93 , ( 7 ) 863 - 871 .
Baker D, Pryce G ( 2008 ) . The endocannabinoid system and multiple sclerosis . Curr Pharm Des vol. 14 , ( 23 ) 2326 - 2336 .
Barth P, Schonbrun J, Baker D ( 2007 ) . Toward high-resolution prediction and design of transmembrane helical protein structures (Proceedings of the National Academy of Sciences of the United States of America (2007) 104, 40, (15682-15687) DOI: 10.1073/pnas. 0702515104) . Proceedings of the National Academy of Sciences of the United States of America vol. 104 , ( 51 )
Baker D, Jackson SJ, Pryce G ( 2007 ) . Cannabinoid control of neuroinflammation related to multiple sclerosis . BRIT J PHARMACOL vol. 152 , ( 5 ) 649 - 654 .
Hoi PM, Visintin C, Okuyama M, Gardiner SM, Kaup SS, Bennett T, Baker D, Selwood DL et al. ( 2007 ) . Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl) benzamide (VSN16) in the rat . BRIT J PHARMACOL vol. 152 , ( 5 ) 751 - 764 .
Pocock JM, Pinteaux-Jones F, Fry VA, Baker D, Heales SJ ( 2007 ) . Metabotropic glutamate receptors on microglia: Switching off toxicity . JOURNAL OF NEUROCHEMISTRY . vol. 102 , 239 - 239 .
Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng XD et al. ( 2007 ) . Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells . NAT MED vol. 13 , ( 4 ) 492 - 497 .
Pryce G, Baker D ( 2007 ) . Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors . BRIT J PHARMACOL vol. 150 , ( 4 ) 519 - 525 .
Baker DJ, Hepple RT ( 2006 ) . Elevated caspase and AIF gene expression correlate with progression of sarcopenia during aging in male F344BN rats . Experimental Gerontology vol. 41 , ( 11 ) 1149 - 1156 .
Baker D, Croxford JL, Pryce G, Jackson SM, Ledent C, Marsicano G, Lutz B, Giovannoni G et al. ( 2006 ) . Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitis . JOURNAL OF NEUROIMMUNOLOGY . vol. 178 , 90 - 91 .
Baker D ( 2006 ) . Protection of axonal damage in experimental antoimmune encephalomyelitis . MULTIPLE SCLEROSIS . vol. 12 , S12 - S13 .
Baker D ( 2006 ) . Role of immunity in neurodegeneration in autoimmune encephalomyelitis . JOURNAL OF NEUROIMMUNOLOGY . vol. 178 , 20 - 20 .
Cabranes A, Pryce G, Baker D, Fernandez-Ruiz J ( 2006 ) . Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice . BRAIN RES vol. 1107 , 199 - 205 .
Hepple RT, Baker DJ, McConkey M, Murynka T, Norris R ( 2006 ) . Caloric restriction protects mitochondrial function with aging in skeletal and cardiac muscles . Rejuvenation Research . vol. 9 , 219 - 222 .
Bilsland LG, Dick JRT, Pryce G, Petrosino S, Di Marzo V, Baker D, Greensmith L ( 2006 ) . Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice . FASEB J vol. 20 , ( 7 ) 1003 - + .
Baker DJ, Greenhaff PL, Timmons JA ( 2006 ) . Glycogen phosphorylase inhibition as a therapeutic target: A review of the recent patent literature . Expert Opinion on Therapeutic Patents vol. 16 , ( 4 ) 459 - 466 .
Baker D, Pryce G, Croxford JL, Yamamura T ( 2006 ) . Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitits . CURRENT TOPICS IN NEUROIMMUNOLOGY . Editors: Tabira, T, Yamamura, T, Kira, J , 109 - 116 .
Cristino L, De Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V ( 2006 ) . Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain . NEUROSCIENCE vol. 139 , ( 4 ) 1405 - 1415 .
Baker D, Pryce G, Davies WL, Hiley CR ( 2006 ) . In silico patent searching reveals a new cannabinoid receptor . TRENDS PHARMACOL SCI vol. 27 , ( 1 ) 1 - 4 .
Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I, De Petrocellis L, Saha B, Mahadevan A et al. ( 2006 ) . New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis . BRIT J PHARMACOL vol. 147 , ( 1 ) 83 - 91 .
Baker DJ, Krause DJ, Howlett RA, Hepple RT ( 2006 ) . Nitric oxide synthase inhibition reduces O<inf>2</inf> cost of force development and spares high-energy phosphates following contractions in pump-perfused rat hindlimb muscles . Experimental Physiology vol. 91 , ( 3 ) 581 - 589 .
Baker DJ, Betik AC, Krause DJ, Hepple RT ( 2006 ) . No decline in skeletal muscle oxidative capacity with aging in long-term calorically restricted rats: Effects are independent of mitochondrial DNA integrity . Journals of Gerontology - Series A Biological Sciences and Medical Sciences vol. 61 , ( 7 ) 675 - 684 .
de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Cabranes A, Pryce G, Baker D, Lopez-Rodriguez M, Ramos JA ( 2006 ) . UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders . EUR NEUROPSYCHOPHARM vol. 16 , ( 1 ) 7 - 18 .
Heijmans N, Smith PA, Morris-Downes MM, Pryce G, Baker D, Donaldson AVJ, 't Hart B, Amor S ( 2005 ) . Encephalitogenic and tolerogenic potential of altered peptide ligands of MOG and PLP in Biozzi ABH mice . J NEUROIMMUNOL vol. 167 , ( 1-2 ) 23 - 33 .
East E, Baker D, Pryce G, Lijnen HR, Cuzner ML, Gverić D ( 2005 ) . A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis . Am J Pathol vol. 167 , ( 2 ) 545 - 554 .
Pryce G, O'Neill JK, Croxford JL, Amor S, Hankey DJ, East E, Giovannoni G, Baker D ( 2005 ) . Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis . J NEUROIMMUNOL vol. 165 , ( 1-2 ) 41 - 52 .
Amor S, Smith PA, 't Hart B, Baker D ( 2005 ) . Biozzi mice: Of mice and human neurological diseases . J NEUROIMMUNOL vol. 165 , ( 1-2 ) 1 - 10 .
Hepple RT, Baker DJ, Kaczor JJ, Krause DJ ( 2005 ) . Long-term caloric restriction abrogates the age-related decline in skeletal muscle aerobic function . FASEB Journal vol. 19 , ( 10 ) 1320 - 1322 .
Smith PA, Morris-Downes M, Heijmans N, Pryce G, Arter E, O'Neill JK, 't Hart B, Baker D et al. ( 2005 ) . Epitope spread is not critical for the relapse and progression of MOG 8-21 induced EAE in Biozzi ABH mice . J NEUROIMMUNOL vol. 164 , ( 1-2 ) 76 - 84 .
Idris AI, Hof RJV, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH ( 2005 ) . Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors . NAT MED vol. 11 , ( 7 ) 774 - 779 .
Jackson SJ, Diemel LT, Pryce G, Baker D ( 2005 ) . Cannabinoids and neuroprotection in CNS inflammatory disease . JOURNAL OF THE NEUROLOGICAL SCIENCES . vol. 233 , 21 - 25 .
Idris AI, Van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH ( 2005 ) . Cannabinoid receptor 1 knockout mice have increased bone mass and are protected from ovariectomy-induced bone loss . BONE . vol. 36 , S132 - S132 .
Pryce G, Baker D ( 2005 ) . Emerging properties of cannabinoid medicines in management of multiple sclerosis . TRENDS NEUROSCI vol. 28 , ( 5 ) 272 - 276 .
Visintin C, Aliev AE, Riddall D, Baker D, Okuyama M, Hoi PM, Hiley R, Selwood DL ( 2005 ) . Membrane receptor probes: Solid-phase synthesis of biotin-Asp-PEG-arvanil derivatives . ORG LETT vol. 7 , ( 9 ) 1699 - 1702 .
Gegg ME, Harry R, Hankey D, Zambarakji H, Pryce G, Baker D, Adamson P, Calder V et al. ( 2005 ) . Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction . J IMMUNOL vol. 174 , ( 4 ) 2327 - 2335 .
Jackson SJ, Pryce G, Diemel LT, Cuzner ML, Baker D ( 2005 ) . Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation . NEUROSCIENCE vol. 134 , ( 1 ) 261 - 268 .
Constantinescu CS, Baker D ( 2005 ) . Cytokines in experimental autoimmune encephalomyelitis . Experimental Models of Multiple Sclerosis ,
Baker D ( 2005 ) . Genetics of experimental allergic encephalomyelitis . Experimental Models of Multiple Sclerosis ,
Baker DJ, Hepple RT ( 2005 ) . The versatility of the pump-perfused rat hindlimb preparation: Examples relating to skeletal muscle function and energy metabolism . Canadian Journal of Applied Physiology . vol. 30 , 576 - 590 .
Jackson SJ, Baker D, Cuzner ML, Diemel LT ( 2004 ) . Cannabinoid-mediated neuroprotection following interferon-gamma treatment in a three-dimensional mouse brain aggregate cell culture . EUR J NEUROSCI vol. 20 , ( 9 ) 2267 - 2275 .
Idris AI, Van't Hof' RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH ( 2004 ) . Regulation of osteoclastic bone resorption and bone mass by the cannabinoid receptor 1 pathway . JOURNAL OF BONE AND MINERAL RESEARCH . vol. 19 , S284 - S284 .
Pryce G, Jackson SM, Hankey DRJ, Giovannoni G, Baker D ( 2004 ) . Cannabinoids are neuroprotective: dissociation of true neuroprotection from protection secondary to immunosuppression . JOURNAL OF NEUROIMMUNOLOGY . vol. 154 , 78 - 78 .
Heijmans N, Smith P, Pryce D, Baker D, Morris-Downes M, Amor S ( 2004 ) . Non-encephalitogenic single amino acid substitutions of MOG 8-21 and PLP 56-70 suppress relapsing EAE in ABH mice . JOURNAL OF NEUROIMMUNOLOGY . vol. 154 , 60 - 60 .
Baker D, Pryce G ( 2004 ) . The potential role of the endocannabinoid system in the control of multiple scleorsis . Current Medicinal Chemistry - Central Nervous System Agents vol. 4 , ( 3 ) 195 - 202 .
East E, Baker D, Pryce G, Cuzner ML, Gveric D ( 2004 ) . The role of plasminogen activators in experimental allergic encephalomyelitis: inflammation and axonal pathology . JOURNAL OF NEUROIMMUNOLOGY . vol. 154 , 167 - 167 .
Ellmerich S, Takacs K, Mycko M, Waldner H, Wahid F, Boyton RJ, Smith PA, Amor S et al. ( 2004 ) . Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis . EUR J IMMUNOL vol. 34 , ( 7 ) 1839 - 1848 .
de Lago E, Ligresti A, Ortar G, Morera E, Cabranes A, Pryce G, Bifulco M, Baker D et al. ( 2004 ) . In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake . EUR J PHARMACOL vol. 484 , ( 2-3 ) 249 - 257 .
Hagen JL, Krause DJ, Baker DJ, Hua Fu M, Tarnopolsky MA, Hepple RT ( 2004 ) . Skeletal muscle aging in F344BN F1-hybrid rats: I. Mitochondrial dysfunction contributes to the age-associated reduction in VO<inf>2max</inf> . Journals of Gerontology - Series A Biological Sciences and Medical Sciences vol. 59 , ( 11 ) 1099 - 1110 .
Hepple RT, Hagen JL, Krause DJ, Baker DJ ( 2004 ) . Skeletal muscle aging in F344BN F1-hybrid rats: II. Improved contractile economy in senescence helps compensate for reduced ATP-generating capacity . Journals of Gerontology - Series A Biological Sciences and Medical Sciences vol. 59 , ( 11 ) 1111 - 1119 .
Wilkinson JD, Whalley BJ, Baker D, Pryce G, Constanti A, Gibbons S, Williamson EM ( 2003 ) . Medicinal cannabis: is Delta(9)-tetrahydrocannabinol necessary for all its effects? . J PHARM PHARMACOL vol. 55 , ( 12 ) 1687 - 1694 .
Pryce G, Ahmed Z, Hankey DJR, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A et al. ( 2003 ) . Cannabinoids inhibit neurodegeneration in models of multiple sclerosis . BRAIN vol. 126 , 2191 - 2202 .
Craner MJ, Kataoka Y, Lo AC, Black JA, Baker D, Waxman SG ( 2003 ) . Temporal course of upregulation of Na-v 1.8 in Purkinje neurons parallels the progression of clinical deficit in experimental allergic encephalomyelitis . J NEUROPATH EXP NEUR vol. 62 , ( 9 ) 968 - 975 .
East E, Baker D, Pryce GM, Cuzner ML, Gveric D ( 2003 ) . The role of plasminogen activators in experimental allergic encephalomyelitis . GLIA . 40 - 40 .
Ahmed Z, Baker D, Cuzner ML ( 2003 ) . Interleukin-12 induces mild experimental allergic encephalomyelitis following local central nervous system injury in the Lewis rat . J NEUROIMMUNOL vol. 140 , ( 1-2 ) 109 - 117 .
Giovannoni G, Baker D ( 2003 ) . Inflammatory disorders of the central nervous system . CURR OPIN NEUROL vol. 16 , ( 3 ) 347 - 350 .
Hall RJ, Hollis-Moffatt JE, Merriman ME, Green RA, Baker D, Merriman TR ( 2003 ) . An autoimmune diabetes locus (Idd21) on mouse Chromosome 18 . MAMM GENOME vol. 14 , ( 5 ) 335 - 339 .
Baker D, Hankey DJR ( 2003 ) . Gene therapy in autoimmune, demyelinating disease of the central nervous system . GENE THER vol. 10 , ( 10 ) 844 - 853 .
Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, Adamson P ( 2003 ) . Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis . FASEB J vol. 17 , ( 8 ) 905 - 907 .
Pryce G, Giovannoni G, Baker D ( 2003 ) . Mifepristone or inhibition of 11 beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice . NEUROSCI LETT vol. 341 , ( 2 ) 164 - 166 .
Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, Giovannoni G ( 2003 ) . Quantification of neurodegeneration by measurement of brain-specific proteins . J NEUROIMMUNOL vol. 138 , ( 1-2 ) 45 - 48 .
Baker D, Pryce G, Giovannoni G, Thompson AJ ( 2003 ) . The therapeutic potential of cannabis . LANCET NEUROL vol. 2 , ( 5 ) 291 - 298 .
Baker D, Pryce G ( 2003 ) . The therapeutic potential of cannabis in multiple sclerosis . EXPERT OPIN INV DRUG vol. 12 , ( 4 ) 561 - 567 .
Craner MJ, Lo AC, Black JA, Baker D, Newcombe J, Cuzner ML, Waxman SG ( 2003 ) . Annexin II/piII is up-regulated in Purkinje cells in EAE and MS . NEUROREPORT vol. 14 , ( 4 ) 555 - 558 .
Baker D, Adamson P, Greenwood J ( 2003 ) . Potential of statins for the treatment of multiple sclerosis . LANCET NEUROL vol. 2 , ( 1 ) 9 - 10 .
Ahmed Z, Doward AI, Pryce G, Taylor DL, Pocock JM, Leonard JP, Baker D, Cuzner ML ( 2002 ) . A role for caspase-1 and-3 in the pathology of experimental allergic encephalomyelitis - Inflammation versus degeneration . AM J PATHOL vol. 161 , ( 5 ) 1577 - 1586 .
Hall RJ, Hollis-Moffat JE, Merriman ME, Bridges RJ, Green RA, Williams G, Baker D, Merriman TR ( 2002 ) . An autoimmune diabetes locus (ldd21) on mouse chromosome 18 . AMERICAN JOURNAL OF HUMAN GENETICS . vol. 71 , 446 - 446 .
Thompson AJ, Baker D ( 2002 ) . Cannabinoids in MS - Potentially useful but not just yet! . NEUROLOGY vol. 58 , ( 9 ) 1323 - 1324 .
Walters CE, Pryce G, Hankey DJR, Sebti SM, Hamilton AD, Baker D, Greenwood J, Adamson P ( 2002 ) . Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis . J IMMUNOL vol. 168 , ( 8 ) 4087 - 4094 .
Morris-Downes MM, Smith PA, Rundle JL, Piddlesden SJ, Baker D, Pham-Dinh D, Heijmans N, Amor S ( 2002 ) . Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice . J NEUROIMMUNOL vol. 125 , ( 1-2 ) 114 - 124 .
Youssef F, Seifalian AM, Jagroop IA, Myint F, Baker D, Mikhailidis DP, Hamilton G ( 2002 ) . The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT)dagger . EUR J VASC ENDOVASC vol. 23 , ( 4 ) 358 - 364 .
Brooks JW, Pryce G, Bisogno T, Jaggar SI, Hankey DJR, Brown P, Bridges D, Ledent C et al. ( 2002 ) . Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors . EUR J PHARMACOL vol. 439 , ( 1-3 ) 83 - 92 .
Morris-Downes MM, McCormack K, Baker D, Sivaprasad D, Natkunarajah J, Amor S ( 2002 ) . Encephalitogenic and immunogenic potential of myelin-associated glycoprotein (MAG), oligodendrocyte-specific glycoprotein (OSP) and 2 ',3 '-cyclic nucleotide 3 '-phosphodiesterase (CNPase) in ABH and SJL mice . J NEUROIMMUNOL vol. 122 , ( 1-2 ) 20 - 33 .
O'Neill JW, Kim DE, Johnsen K, Baker D, Zhang KYJ ( 2001 ) . Single-site mutations induce 3D domain swapping in the B1 domain of Protein L from Peptostreptococcus magnus . Structure vol. 9 , ( 11 ) 1017 - 1027 .
Hankey DJR, Nickerson JM, Donoso LA, Lightman SL, Baker D ( 2001 ) . Experimental autoimmune uveoretinitis in mice (Biozzi ABH and NOD) expressing the autoimmune-associated H-2A(g7) molecule: identification of a uveitogenic epitope . J NEUROIMMUNOL vol. 118 , ( 2 ) 212 - 222 .
Generini S, Matucci-Cerinic M, Partsch G, Stancikova M, Pignone A, Konttinen YT, Rovensky J, Baker DJ et al. ( 2001 ) . Evidence for hyaluronan production in the air pouch model in rats . Clinical and Experimental Rheumatology vol. 19 , ( 3 ) 271 - 276 .
Ahmed Z, Gveric D, Pryce G, Baker D, Leonard JP, Cuzner ML, Diemel LT ( 2001 ) . Myelin/axonal pathology in interleukin-12 induced serial relapses of experimental allergic encephalomyelitis in the Lewis rat . Am J Pathol vol. 158 , ( 6 ) 2127 - 2138 .
Croxford JL, Feldmann M, Chernajovsky Y, Baker D ( 2001 ) . Different therapeutic outcomes in experimental allergic encephalomyelitis dependant upon the mode of delivery of IL-10: A comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system . J IMMUNOL vol. 166 , ( 6 ) 4124 - 4130 .
Reichel MB, Bainbridge J, Baker D, Thrasher AJ, Bhattacharya SS, Ali RR ( 2001 ) . An immune response after intraocular administration of an adenoviral vector containing a beta galactosidase reporter gene slows retinal degeneration in the rd mouse . BRIT J OPHTHALMOL vol. 85 , ( 3 ) 341 - 344 .
Hankey DJR, Lightman SL, Baker D ( 2001 ) . Interphotoreceptor retinoid binding protein peptide-induced uveitis in B10.RIII mice: Characterization of disease parameters and immunomodulation . EXP EYE RES vol. 72 , ( 3 ) 341 - 350 .
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L et al. ( 2001 ) . Endocannabinoids control spasticity in a multiple sclerosis model . FASEB J vol. 15 , ( 2 ) 300 - 302 .
Black JA, Dib-Hajj S, Baker D, Newcombe J, Cuzner ML, Waxman SG ( 2000 ) . Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis . Proceedings of the National Academy of Sciences of the United States of America vol. 97 , ( 21 ) 11598 - 11602 .
Chernajovsky Y, Dreja H, Daly G, Annenkov A, Gould D, Adams G, Croxford JL, Baker D et al. ( 2000 ) . Immuno- and genetic therapy in autoimmune diseases . Genes Immun vol. 1 , ( 5 ) 295 - 307 .
Baker D ( 2000 ) . Reply: a sanguine approach to cannabis . Trends Pharmacol Sci vol. 21 , ( 6 )
Thoua NM, van Noort JM, Baker D, Bose A, van Sechel AC, van Stipdonk MJB, Travers PJ, Amor S ( 2000 ) . Encephalitogenic and immunogenic potential of the stress protein alpha B-crystallin in Biozzi ABH (H-2A(g7)) mice . JOURNAL OF NEUROIMMUNOLOGY vol. 104 , ( 1 ) 47 - 57 .
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L ( 2000 ) . Cannabinoids control spasticity and tremor in a multiple sclerosis model . Nature vol. 404 , ( 6773 ) 84 - 87 .
Croxford JL, Triantaphyllopoulos KA, Neve RM, Feldmann M, Chernajovsky Y, Baker D ( 2000 ) . Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor . J Immunol vol. 164 , ( 5 ) 2776 - 2781 .
Chernajovsky Y, Gould D, Annenkov A, Dreja H, Daly G, Rabinovich GA, Croxford L, Baker D et al. ( 1999 ) . Immunotherapy of auto-immune diseases by gene transfer . Biochem Soc Trans vol. 27 , ( 6 ) 869 - 873 .
Brennan FR, O'Neill JK, Allen SJ, Butter C, Nuki G, Baker D ( 1999 ) . CD44 is involved in selective leucocyte extravasation during inflammatory central nervous system disease . Immunology vol. 98 , ( 3 ) 427 - 435 .
Chernajovsky Y, Gould D, Annenkov A, Dreja H, Daly G, Rabinovich GA, Croxford L, Baker D et al. ( 1999 ) . IMMUNOTHERAPY OF AUTOIMMUNE DISEASES BY GENE TRANSFER . Biochemical Society Transactions vol. 27 , ( 5 ) a137 - a137 .
Croxford JL, O'Neill JK, Ali RR, Browne K, Byrnes AP, Dallman MJ, Wood MJ, Fedlmann M et al. ( 1998 ) . Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis . Eur J Immunol vol. 28 , ( 12 ) 3904 - 3916 .
Ali RR, Reichel MB, Byrnes AP, Stephens CJ, Thrasher AJ, Baker D, Hunt DM, Bhattacharya SS ( 1998 ) . Co-injection of adenovirus expressing CTLA4-Ig prolongs adenovirally mediated lacZ reporter gene expression in the mouse retina . GENE THERAPY vol. 5 , ( 11 ) 1561 - 1565 .
Croxford JL, Ali R, Byrnes A, Dallman M, Feldmann M, Baker D ( 1998 ) . Adenoviral gene therapy of experimental allergic encephalomyelitis (EAE) with CTLA4-Ig . Journal of Neuroimmunology vol. 90 , ( 1 )
Thoua N-M, van Noort J, van Sechel A, van Stipdonk M, Baker D, Amor S ( 1998 ) . Encephalitogenicity of the stress protein α-Crystallin in biozzi ABH mice . Journal of Neuroimmunology vol. 90 , ( 1 )
Croxford JL, Triantaphyllopolous K, Feldmann M, Chernajovsky Y, Baker D ( 1998 ) . Gene therapy of experimental allergic encephalomyelitis (EAE) with dimeric TNF receptors using cells as biological pumps . Journal of Neuroimmunology vol. 90 , ( 1 )
Croxford JL, Triantaphyllopoulos K, Podhajcer OL, Feldmann M, Baker D, Chernajovsky Y ( 1998 ) . Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system . J Immunol vol. 160 , ( 10 ) 5181 - 5187 .
O'Neill JK, Baker D, Morris MM, Gschmeissner SE, Jenkins HG, Butt AM, Kirvell SL, Amor S ( 1998 ) . Optic neuritis in chronic relapsing experimental allergic encephalomyelitis in Biozzi ABH mice: Demyelination and fast axonal transport changes in disease . JOURNAL OF NEUROIMMUNOLOGY vol. 82 , ( 2 ) 210 - 218 .
Chernajovsky Y, Annenkov A, Herman C, Triantaphyllopoulos K, Gould D, Dreja H, Moyes SP, Croxford JL et al. ( 1998 ) . Gene therapy for rheumatoid arthritis. Theoretical considerations . Drugs and Aging vol. 12 , ( 1 ) 29 - 41 .
Triantaphyllopoulos KA, Croxford JL, Baker D, Chernajovsky Y ( 1998 ) . Cloning and expression of murine IFNβ and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis . Gene Therapy vol. 5 , ( 2 ) 253 - 263 .
Reichel MB, Ali RR, Thrasher AJ, Hunt DM, Bhattacharya SS, Baker D ( 1998 ) . Immune responses limit adenovirally mediated gene expression in the adult mouse eye . Gene Therapy vol. 5 , ( 8 ) 1038 - 1046 .
Reichet MB, All RR, Baker D, Byrnes AP, D'Esposito F, Kanuga N, Hunt DM, Bhattacharya SS ( 1997 ) . Co-injection of adenovirus expressing CTLA4-IG prolongs adenovirally-mediated lacz reporter gene expression in the mouse retina . Investigative Ophthalmology and Visual Science vol. 38 , ( 4 )
Thoua NM, van Noort JM, Morris MM, Baker D, Travers PJ, Amor S ( 1997 ) . The heat shock protein αB-crystallin induces EAE in Blozzi ABH mice . Immunology Letters vol. 56 ,
Croxford JL, O'Neill JK, Baker D ( 1997 ) . Polygenic control of experimental allergic encephalomyelitis in Biozzi ABH and BALB/c mice . J Neuroimmunol vol. 74 , ( 1-2 ) 205 - 211 .
Morris MM, Dyson H, Baker D, Harbige LS, Fazakerley JK, Amor S ( 1997 ) . Characterization of the cellular and cytokine response in the central nervous system following Semliki Forest virus infection . Journal of Neuroimmunology vol. 74 , ( 1-2 ) 185 - 197 .
Amor S, Baker D, Layward L, McCormack K, Van Noort JM ( 1997 ) . Multiple sclerosis: Variants on a theme . Immunology Today vol. 18 , ( 8 ) 368 - 371 .
Bolton C, O’ Neill JK, Allen SJ, Baker D ( 1997 ) . Regulation of Chronic Relapsing Experimental Allergic Encephalomyelitis by Endogenous and Exogenous Glucocorticoids . International Archives of Allergy and Immunology vol. 114 , ( 1 ) 74 - 80 .
Brennan FR, ONeill JK, Allen SJ, Mikecz K, Glant TT, Nuki G, Baker D ( 1996 ) . Anti-CD44 antibody prevents and ameriolates chronic relapsing experimental allergic encephalomyelitis (CREAE) by inhibition leukocyte migration to the CNS . ARTHRITIS AND RHEUMATISM vol. 39 , ( 9 ) 625 - 625 .
Amor S, O'Neill JK, Morris MM, Smith RM, Wraith DC, Groome N, Travers PJ, Baker D ( 1996 ) . Encephalitogenic epitopes of myelin basic protein, proteolipid protein, and myelin oligodendrocyte glycoprotein for experimental allergic encephalomyelitis induction in Biozzi ABH (H-2A<sup>g7</sup>) mice share an amino acid motif . Journal of Immunology vol. 156 , ( 8 ) 3000 - 3008 .
Baker D, Rosenwasser OA, O'Neill JK, Turk JL ( 1995 ) . Genetic analysis of experimental allergic encephalomyelitis in mice . Journal of Immunology vol. 155 , ( 8 ) 4046 - 4051 .
Gu H, Yi Q, Bray ST, Riddle DS, Baker D, Shiau AK ( 1995 ) . A phage display system for studying the sequence determinants of protein folding . Protein Science vol. 4 , ( 6 ) 1108 - 1117 .
Amor S, Groome N, Linington C, Morris MM, Dornmair K, Gardinier MV, Matthieu JM, Baker D ( 1994 ) . Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice . Journal of Immunology vol. 153 , ( 10 ) 4349 - 4356 .
Lapa-e-Silva JR, Pretolani M, Bachelet CM, Baker D, Scheper RJ, Vargaftig BB ( 1994 ) . Emergence of T-lymphocytes, eosinophils and dendritic cells in the bronchi of actively sensitized guinea pigs after antigenic challenge . Braz J Med Biol Res vol. 27 , ( 7 ) 1653 - 1658 .
Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M ( 1994 ) . Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor‐immunoglobulin fusion proteins . European Journal of Immunology vol. 24 , ( 9 ) 2040 - 2048 .
Preece NE, Amor S, Baker D, Gadian DG, O'Neill JK, Urenjak J ( 1994 ) . Experimental encephalomyelitis modulates inositol and taurine in the spinal cord of biozzi mice . Magnetic Resonance in Medicine vol. 32 , ( 6 ) 692 - 697 .
Lapa e Silva JR, Bachelet CM, Pretolani M, Baker D, Scheper RJ, Vargaftig BB ( 1993 ) . Immunopathologic alterations in the bronchi of immunized guinea pigs . Am J Respir Cell Mol Biol vol. 9 , ( 1 ) 44 - 53 .
Preece NE, Baker D, Butter C, Gadian DG, Urenjak J ( 1993 ) . Experimental allergic encephalomyelitis raises betaine levels in the spinal cord of strain 13 guinea-pigs . NMR Biomed vol. 6 , ( 3 ) 194 - 200 .
Lapa e Silva JR, Pretolani M, Bachelet CM, Baker D, Shepper RJ, Vargaftig BB ( 1993 ) . Immunohistochemical characterization of T lymphocytes and eosinophils in the bronchial wall of actively sensitized guinea pigs . Chest vol. 103 , ( 2 Suppl ) 130S - 132S .
Fairchild S, Baker D, Turk JL ( 1993 ) . Characterization of experimental allergic encephalomyelitis-susceptible Biozzi AB/H(H-2(dq1)) mice which express H-2A(nod): Analysis of T-cell receptor expression and the detection of a deletion ligand encoded by Mtv-7 . Immunology vol. 78 , ( 2 ) 260 - 265 .
Liu GY, Baker D, Fairchild S, Figueroa F, Quartey-Papafio R, Tone M, Healey D, Cooke A et al. ( 1993 ) . Complete characterization of the expressed immune response genes in Biozzi AB/H mice: structural and functional identity between AB/H and NOD A region molecules . Immunogenetics vol. 37 , ( 4 ) 296 - 300 .
O'Neill JK, Baker D, Davidson AN, Allen SJ, Butter C, Waldmann H, Turk JL ( 1993 ) . Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies . Journal of Neuroimmunology vol. 45 , ( 1-2 ) 1 - 14 .
Amor S, Baker D, Groome N, Turk JL ( 1993 ) . Identification of a major encephalitogenic epitope of proteolipid protein (residues 56-70) for the induction of experimental allergic encephalomyelitis in Biozzi AB/H and nonobese diabetic mice . Journal of Immunology vol. 150 , ( 12 ) 5666 - 5672 .
Allen SJ, Baker D, O’Neill JK, Davison AN, Turk JL ( 1993 ) . Isolation and characterization of cells infiltrating the spinal cord during the course of chronic relapsing experimental allergic encephalomyelitis in the biozzi ab/h mouse . Cellular Immunology vol. 146 , ( 2 ) 335 - 350 .
Lapa E Silva JR, Pretolani M, Bachelet CM, Baker D, Scheper R, Vargaftig BB ( 1992 ) . Booster-Dependent Alterations of the Subsets of T Lymphocytes and Eosinophils in the Bronchi of Immunized Guinea Pigs . Int Arch Allergy Immunol vol. 99 , ( 2-4 ) 350 - 353 .
Baker D, O'Neill JK, Davison AN, Turk JL ( 1992 ) . Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: Elucidation by the action of mitoxantrone . Clinical and Experimental Immunology vol. 90 , ( 1 ) 124 - 128 .
O'Neill JK, Baker D, Turk JL ( 1992 ) . Inhibition of chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse . Journal of Neuroimmunology vol. 41 , ( 2 ) 177 - 187 .
O'Neill JK, Baker D, Davison AN, Maggon KK, Jaffee BD, Turk JL ( 1992 ) . Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood-brain barrier: elucidation by the action of Brequinar sodium . Journal of Neuroimmunology vol. 38 , ( 1-2 ) 53 - 62 .
Kimber I, Foster JR, Baker D, Turk JL ( 1991 ) . Selective impairment of T lymphocyte activation following contact sensitization with oxazolone . International Archives of Allergy and Applied Immunology vol. 95 , ( 2-3 ) 142 - 148 .
Baker D, Davison AN ( 1991 ) . Mechanisms of immune-mediated demyelinating disease of the central nervous system . Neurochemical Research vol. 16 , ( 9 ) 1067 - 1072 .
Butter C, O'Neill JK, Baker D, Gschmeissner SE, Turk JL ( 1991 ) . An immunoelectron microscopical study of the expression of class II major histocompatibility complex during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice . J Neuroimmunol vol. 33 , ( 1 ) 37 - 42 .
Butter C, Baker D, O'Neill JK, Turk JL ( 1991 ) . Mononuclear cell trafficking and plasma protein extravasation into the CNS during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice . J Neurol Sci vol. 104 , ( 1 ) 9 - 12 .
Baker D, Kimber I, Ahmed K, Turk JL ( 1991 ) . Antigen-specific and non-specific depression of proliferative responses induced during contact sensitivity in mice . International Journal of Experimental Pathology vol. 72 , ( 1 ) 55 - 65 .
Baker D, O'Neill JK, Turk JL ( 1991 ) . Cytokines in the central nervous system of mice during chronic relapsing experimental allergic encephalomyelitis . Cellular Immunology vol. 134 , ( 2 ) 505 - 510 .
O'Neill JK, Butter C, Baker D, Gschmeissner SE, Kraal G, Butcher EC, Turk JL ( 1991 ) . Expression of vascular addressins and ICAM-1 by endothelial cells in the spinal cord during chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse . Immunology vol. 72 , ( 4 ) 520 - 525 .
Baker D, O'Neill JK, Amor S, Khamashta MA, Turk JL ( 1991 ) . Inhibition of chronic relapsing experimental allergic encephalomyelitis in the mouse by the alkyl-lysophospholipid ET-18-OCH<inf>3</inf> . International Journal of Immunopharmacology vol. 13 , ( 4 ) 385 - 392 .
Watson CM, Davison AN, Baker D, O'Neill JK, Turk JL ( 1991 ) . Suppression of demyelination by mitoxantrone . Int J Immunopharmacol vol. 13 , ( 7 ) 923 - 930 .
Wilcox CE, Ward AM, Evans A, Baker D, Rothlein R, Turk JL ( 1990 ) . Endothelial cell expression of the intercellular adhesion molecule-1 (ICAM-1) in the central nervous system of guinea pigs during acute and chronic relapsing experimental allergic encephalomyelitis . J Neuroimmunol vol. 30 , ( 1 ) 43 - 51 .
Kimber I, Cumberbatch M, Bentley AN, Baker D ( 1990 ) . Requirements for antigenic competition in contact sensitivity . J Clin Lab Immunol vol. 32 , ( 2 ) 67 - 72 .
Kimber I, Bentley AN, Ward RK, Baker D, Turk JL ( 1990 ) . Antigen-restricted antigenic competition induced by 2, 4-dinitrochlorobenzene: Association with depression of lymphocyte proliferation . International Archives of Allergy and Immunology vol. 91 , ( 3 ) 316 - 322 .
Baker D, O'Neill JK, Gschmeissner SE, Wilcox CE, Butter C, Turk JL ( 1990 ) . Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice . Journal of Neuroimmunology vol. 28 , ( 3 ) 261 - 270 .
Schäfer H, Baker D, Thiele B, Burger R ( 1990 ) . Structure, cellular distribution, and functional characteristics of the guinea pig leucocyte common antigen . Cellular Immunology vol. 128 , ( 2 ) 370 - 384 .
Butter C, Healey DG, Baker D, Turk JL ( 1989 ) . A quantitative immunocytochemical study of the infiltrating lymphocytes in the spinal cord of guinea pigs with chronic relapsing experimental allergic encephalomyelitis . J Neuroimmunol vol. 25 , ( 2-3 ) 169 - 176 .
Wilcox CE, Healey DG, Baker D, Willoughby DA, Turk JL ( 1989 ) . Presentation of myelin basic protein by normal guinea-pig brain endothelial cells and its relevance to experimental allergic encephalomyelitis . Immunology vol. 67 , ( 4 ) 435 - 440 .
Wilcox CE, Baker D, Butter C, Willoughby DA, Turk JL ( 1989 ) . Differential expression of guinea pig class II major histocompatibility complex antigens on vascular endothelial cells in vitro and in experimental allergic encephalomyelitis . Cell Immunol vol. 120 , ( 1 ) 82 - 91 .
Baker D, Kimber I, Turk JL ( 1989 ) . Antigen-specific regulation of T lymphocyte proliferative responses to contact-sensitizing chemicals in the guinea pig . Cellular Immunology vol. 119 , ( 1 ) 153 - 159 .
Kimber I, Shepherd CJ, Mitchell JA, Turk JL, Baker D ( 1989 ) . Regulation of lymphocyte proliferation in contact sensitivity: Homeostatic mechanisms and a possible explanation of antigenic competition . Immunology vol. 66 , ( 4 ) 577 - 582 .
Kraal G, Shiamatey-Koolma R, Hoffer M, Baker D, Scheper R ( 1988 ) . Histochemical identification of guinea-pig macrophages by monoclonal antibody MR-1 . Immunology vol. 65 , ( 4 ) 523 - 528 .
Baker D, Healey DG, Verghese S, Schafer H, Turk JL ( 1988 ) . Phenotypic analysis of guinea pig langerhans cells with antibodies directed against leucocyte surface antigens . International Archives of Allergy and Immunology vol. 86 , ( 3 ) 350 - 355 .
Baker D, Parker D, Healey DG, Turk JL ( 1987 ) . Induction of sensitization and tolerance in contact sensitivity with haptenated epidermal cells in the guinea-pig . Immunology vol. 62 , ( 4 ) 659 - 664 .
Healey DG, Baker D, Gschmeissner SE, Turk JL ( 1987 ) . An antigenic determinant common to lymphocytes and Langerhans cells of the guinea pig . International Archives of Allergy and Applied Immunology vol. 82 , ( 2 ) 120 - 124 .
Antoniou AV, Baker D, El-Sady E, Turk JL, Tan BTG, Scheper RJ ( 1987 ) . Identification and quantitation of the expression of T cell surface markers during the development of chronic relapsing experimental allergic encephalomyelitis (CREAE) in the guinea pig . Journal of Neuroimmunology vol. 14 , ( 3 ) 293 - 303 .
BAKER D, PARKER DD, TURK JL ( 1985 ) . Effect of depletion of epidermal dendritic cells on the induction of contact sensitivity in the guinea‐pig . British Journal of Dermatology vol. 113 , ( 3 ) 285 - 294 .